Connecting via Winsock to STN

Welcome to STN International! Enter x:x

Thank you for accessing STN

Our services are currently unavailable. The regularly scheduled hours of operations are:

US Eastern time: Sunday from 01:00 (1:00 AM) until Saturday at 22:00 (10:00 PM)

On the first Saturday of each month, STN is available only until 17:00 (5:00 PM).

Tokyo time: Sunday from 14:00 (2:00 PM) until Sunday at 11:00 (11:00 AM)

On the Sunday of the first weekend of each month, STN is available only until 06:00 (6:00 AM).

Additionally, representatives from the Help Desk and Customer Service may be reached from 08:00 (8:00 AM) to 20:00 (8:00 PM) US Eastern time, Monday through Friday, at the following telephone numbers:

Help Desk	- (800) 848-6533	North America
	- (614) 447-3698	Elsewhere
Customer Service	- (800) 753-4227	North America
	- (614) 447-3731	Elsewhere

We can also be contacted via email at HELP@CAS.ORG.

Connection closed by remote host

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspt189dxw

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America

```
 NEWS  2  JAN 02  STN pricing information for 2008 now available
 NEWS  3  JAN 16  CAS patent coverage enhanced to include exemplified
                  prophetic substances
 NEWS  4  JAN 28  USPATFULL, USPAT2, and USPATOLD enhanced with new
                  custom IPC display formats
 NEWS  5  JAN 28  MARPAT searching enhanced
 NEWS  6  JAN 28  USGENE now provides USPTO sequence data within 3 days
                  of publication
 NEWS  7  JAN 28  TOXCENTER enhanced with reloaded MEDLINE segment
 NEWS  8  JAN 28  MEDLINE and LMEDLINE reloaded with enhancements
 NEWS  9  FEB 08  STN Express, Version 8.3, now available
 NEWS 10  FEB 20  PCI now available as a replacement to DPCI
 NEWS 11  FEB 25  IFIREF reloaded with enhancements
 NEWS 12  FEB 25  IMSPRODUCT reloaded with enhancements
 NEWS 13  FEB 29  WPINDEX/WPIDS/WPIX enhanced with ECLA and current
                  U.S. National Patent Classification
 NEWS 14  MAR 31  IFICDB, IFIPAT, and IFIUDB enhanced with new custom
                  IPC display formats
 NEWS 15  MAR 31  CAS REGISTRY enhanced with additional experimental
                  spectra
 NEWS 16  MAR 31  CA/CAplus and CASREACT patent number format for U.S.
                  applications updated
 NEWS 17  MAR 31  LPCI now available as a replacement to LDPCI
 NEWS 18  MAR 31  EMBASE, EMBAL, and LEMBASE reloaded with enhancements
 NEWS 19  APR 04  STN AnaVist, Version 1, to be discontinued

 NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:48:10 ON 13 APR 2008

=> index bioscience
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
       AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,
       CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB,
       DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 13:48:31 ON 13 APR 2008

69 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.
```

```
=> s prevent?(p)scar? and (coat? or impreg?) and (bandage or gauze) and (ancrod or
urokinase or streptokinase or phenobarbital or valproic acid)
          0*  FILE ADISNEWS
          0*  FILE ANTE
          0*  FILE AQUALINE
          0*  FILE BIOENG
          0*  FILE BIOTECHABS
          0*  FILE BIOTECHDS
          0*  FILE BIOTECHNO
          1   FILE CAPLUS
          0*  FILE CEABA-VTB
          0*  FILE CIN
  17 FILES SEARCHED...
  23 FILES SEARCHED...
          0*  FILE ESBIOBASE
          0*  FILE FOMAD
          0*  FILE FOREGE
          0*  FILE FROSTI
          0*  FILE FSTA
          1   FILE IFIPAT
          0*  FILE KOSMET
  43 FILES SEARCHED...
          0*  FILE NTIS
          0*  FILE NUTRACEUT
          0*  FILE PASCAL
          0*  FILE PHARMAML
        403   FILE USPATFULL
  61 FILES SEARCHED...
         69   FILE USPAT2
          0*  FILE WATER
          2   FILE WPIDS
          2   FILE WPINDEX

   6 FILES HAVE ONE OR MORE ANSWERS,   69 FILES SEARCHED IN STNINDEX

L1   QUE PREVENT?(P) SCAR? AND (COAT? OR IMPREG?) AND (BANDAGE OR GAUZE) AND (A
         NCROD OR UROKINASE OR STREPTOKINASE OR PHENOBARBITAL OR VALPROIC ACID)


=> file caplus ifipat uspatfull uspat2
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                   3.25       3.46

FILE 'CAPLUS' ENTERED AT 13:51:27 ON 13 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'IFIPAT' ENTERED AT 13:51:27 ON 13 APR 2008
COPYRIGHT (C) 2008 IFI CLAIMS(R) Patent Services (IFI)

FILE 'USPATFULL' ENTERED AT 13:51:27 ON 13 APR 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 13:51:27 ON 13 APR 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l1
L2         474 L1

=> dup rem l2
```

```
PROCESSING COMPLETED FOR L2
L3          405 DUP REM L2 (69 DUPLICATES REMOVED)

=> s l3 and (ancrod or urokinase or streptokinase or valproic acid)
L4         383 L3 AND (ANCROD OR UROKINASE OR STREPTOKINASE OR VALPROIC ACID)

=> s L4 and (bandage or gauze)
L5         383 L4 AND (BANDAGE OR GAUZE)

=> s L4 and (bandage or gauze pad)
L6         151 L4 AND (BANDAGE OR GAUZE PAD)

=> s L6 and injury
L7         142 L6 AND INJURY

=> s L7 and first aid
L8           1 L7 AND FIRST AID

=> d l8 1

L8   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2008 ACS on STN
AN   2004:964610  CAPLUS
DN   141:401038
TI   Ancrod irradiated, impregnated or coated
     sutures and other first aid or wound management
     bandaging materials for minimizing and/or preventing excessive
     scar formation
IN   Raffaniello, Samn
PA   USA
SO   U.S. Pat. Appl. Publ., 4 pp.
     CODEN: USXXCO
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
PI   US 20040224006       A1    20041111    US 2004-829143         20040421
PRAI US 2003-464229P      P     20030421


=> s L7 and prevent?(p)scar?
L9         142 L7 AND PREVENT?(P) SCAR?

=> s L9 and scarring
L10        136 L9 AND SCARRING

=> s L10 and prevent scarr?
L11          1 L10 AND PREVENT SCARR?

=> d l11 1

L11  ANSWER 1 OF 1  USPATFULL on STN
AN     2007:114745  USPATFULL
TI     Methods and compositions for blocking platelet and cell adhesion, cell
       migration and inflammation
IN     Glidden, Paul F., San Diego, CA, UNITED STATES
PI     US 2007099819       A1  20070503
AI     US 2006-540203      A1  20060928 (11)
PRAI   US 2005-721754P     20050928 (60)
DT     Utility
FS     APPLICATION
LN.CNT 2315
```

INCL INCLM: 514/002.000
NCL   NCLM: 514/002.000
IC   IPCI   A61K0038-17 [I,A]
      IPCR   A61K0038-17 [I,C]; A61K0038-17 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s L9 and coated bandage
L12   0 L9 AND COATED BANDAGE

=> s L9 and coated(p)bandage?
L13   20 L9 AND COATED(P) BANDAGE?

=> d l13 1-20

L13 ANSWER 1 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN
AN   2004:964610 CAPLUS
DN   141:401038
TI   Ancrod irradiated, impregnated or coated
     sutures and other first aid or wound management bandaging materials for
     minimizing and/or preventing excessive scar formation
IN   Raffaniello, Samn
PA   USA
SO   U.S. Pat. Appl. Publ., 4 pp.
     CODEN: USXXCO
DT   Patent
LA   English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20040224006	A1	20041111	US 2004-829143	20040421
PRAI	US 2003-464229P	P	20030421		

L13 ANSWER 2 OF 20 USPATFULL on STN
AN   2008:36416 USPATFULL
TI   THIOLATED MACROMOLECULES AND METHODS OF MAKING AND USING THEREOF
IN   Prestwich, Glenn D., Salt Lake City, UT, UNITED STATES
       Serban, Monica, Salt Lake City, UT, UNITED STATES
PI   US 2008031854   A1 20080207
AI   US 2007-776519   A1 20070711 (11)
PRAI   US 2006-806965P   20060711 (60)
DT   Utility
FS   APPLICATION
LN.CNT 1841
INCL   INCLM: 424/093.100
       INCLS: 435/001.100; 435/325.000; 514/025.000; 530/350.000; 536/017.600;
              536/055.200
NCL   NCLM: 424/093.100
       NCLS: 435/001.100; 435/325.000; 514/025.000; 530/350.000; 536/017.600;
              536/055.200
IC   IPCI   A61K0031-7008 [I,A]; A01N0001-02 [I,A]; A61K0045-00 [I,A];
              A61P0017-02 [I,A]; A61P0017-00 [I,C*]; A61P0041-00 [I,A];
              C07H0015-00 [I,A]; C07H0005-04 [I,A]; C07H0005-00 [I,C*];
              C07K0014-00 [I,A]; C12N0005-06 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 3 OF 20 USPATFULL on STN
AN   2007:257685 USPATFULL
TI   Sealants for Skin and Other Tissues
IN   Bowlin, Gary L., Mechanicsville, VA, UNITED STATES
       Simpson, David G., Mechanicsville, VA, UNITED STATES
       Wnek, Gary E., Cleveland, OH, UNITED STATES

Carr, Marcus E. JR., Holland, PA, UNITED STATES
Stevens, Peter J., N. Richland Hills, TX, UNITED STATES
Cadd, Gary, Grapevine, TX, UNITED STATES
Cohen, I. Kelman, Richmond, VA, UNITED STATES
PI US 2007225631 A1 20070927
AI US 2003-588344 A1 20031006 (10)
WO 2003-US31637 20031006
20070108 PCT 371 date
PRAI US 2002-416026P 20021004 (60)
US 2002-425949P 20021113 (60)
DT Utility
FS APPLICATION
LN.CNT 4946
INCL INCLM: 602/052.000
INCLS: 205/050.000; 530/356.000
NCL NCLM: 602/052.000
NCLS: 205/050.000; 530/356.000
IC IPCI A61F0013-00 [I,A]; A61K0038-17 [I,A]; C07K0001-00 [I,A]
IPCR A61F0013-00 [I,C]; A61F0013-00 [I,A]; A61K0038-17 [I,C];
A61K0038-17 [I,A]; C07K0001-00 [I,C]; C07K0001-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 4 OF 20 USPATFULL on STN
AN 2006:174046 USPATFULL
TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2006147492 A1 20060706
AI US 2006-343809 A1 20060131 (11)
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2003-518785P 20031110 (60)
DT Utility
FS APPLICATION
LN.CNT 56233
INCL INCLM: 424/426.000
NCL NCLM: 424/426.000
IC IPCI A61F0002-00 [I,A]; A61K0031-47 [I,A]
IPCR A61F0002-00 [I,A]; A61F0002-00 [I,C]; A61F0002-02 [I,C*];
A61F0002-02 [I,A]; A61F0002-04 [I,C*]; A61F0002-04 [I,A];
A61F0002-06 [I,C*]; A61F0002-06 [I,A]; A61F0002-28 [I,C*];
A61F0002-28 [I,A]; A61F0002-44 [I,C*]; A61F0002-44 [I,A];
A61K0031-47 [I,C]; A61K0031-47 [I,A]; A61K0038-00 [I,C*];
A61K0038-00 [I,A]; A61L0031-14 [I,C*]; A61L0031-16 [I,A];
A61M0016-04 [I,C*]; A61M0016-04 [I,A]; A61M0031-00 [I,C*];
A61M0031-00 [I,A]; A61N0001-05 [I,C*]; A61N0001-05 [I,A];
A62B0009-00 [I,C*]; A62B0009-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 5 OF 20 USPATFULL on STN
AN 2005:240095 USPATFULL
TI Polymer compositions and methods for their use

IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A. E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005208095 A1 20050922
AI US 2004-996354 A1 20041122 (10)
RLI Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LN.CNT 34089
INCL INCLM: 424/423.000
NCL NCLM: 424/423.000
IC [7]
ICM A61F002-00
IPCI A61F0002-00 [ICM,7]
IPCR A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61L0027-00 [I,C*];
A61L0027-54 [I,A]; A61L0031-14 [I,C*]; A61L0031-16 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 6 OF 20 USPATFULL on STN
AN 2005:220596 USPATFULL
TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005191331 A1 20050901
AI US 2004-1419 A1 20041130 (11)
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2003-518785P 20031110 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2003-525226P 20031124 (60)
US 2003-526541P 20031203 (60)
US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
DT Utility
FS APPLICATION
LN.CNT 56419
INCL INCLM: 424/423.000
NCL NCLM: 424/423.000
IC [7]
ICM A61F002-00
IPCI A61F0002-00 [ICM,7]
IPCR A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-02 [I,C*];
A61F0002-02 [I,A]; A61F0002-04 [I,C*]; A61F0002-04 [I,A];
A61F0002-06 [I,C*]; A61F0002-06 [I,A]; A61F0002-28 [I,C*];
A61F0002-28 [I,A]; A61F0002-44 [I,C*]; A61F0002-44 [I,A];

A61K0038-00 [I,C*]; A61K0038-00 [I,A]; A61L0031-14 [I,C*];
A61L0031-16 [I,A]; A61M0016-04 [I,C*]; A61M0016-04 [I,A];
A61M0031-00 [I,C*]; A61M0031-00 [I,A]; A61N0001-05 [I,C*];
A61N0001-05 [I,A]; A62B0009-00 [I,C*]; A62B0009-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 7 OF 20 USPATFULL on STN
AN 2005:220513 USPATFULL
TI Medical implants and fibrosis-inducing agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005191248 A1 20050901
AI US 2004-6907 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2003-518785P 20031110 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
DT Utility
FS APPLICATION
LN.CNT 42940
INCL INCLM: 424/050.000
INCLS: 433/217.100
NCL NCLM: 424/050.000
NCLS: 433/217.100
IC [7]
ICM A61K007-28
ICS A61C005-00
IPCI A61K0007-28 [ICM,7]; A61C0005-00 [ICS,7]
IPCR A61B0017-03 [I,C*]; A61B0017-11 [I,A]; A61B0017-12 [I,C*];
A61B0017-12 [I,A]; A61C0005-00 [I,C*]; A61C0005-00 [I,A];
A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-28 [I,C*];
A61F0002-28 [I,A]; A61F0013-00 [I,C*]; A61F0013-00 [I,A];
A61K0031-045 [I,C*]; A61K0031-045 [I,A]; A61K0031-4738 [I,C*];
A61K0031-4745 [I,A]; A61K0031-513 [I,C*]; A61K0031-513 [I,A];
A61K0031-519 [I,C*]; A61K0031-525 [I,A]; A61K0031-65 [I,C*];
A61K0031-65 [I,A]; A61K0031-70 [I,C*]; A61K0031-70 [I,A];
A61K0031-7012 [I,C*]; A61K0031-7012 [I,A]; A61K0031-7028 [I,C*];
A61K0031-704 [I,A]; A61K0031-7042 [I,C*]; A61K0031-7048 [I,A];
A61K0031-7072 [I,A]; A61K0031-74 [I,C*]; A61K0031-765 [I,A];
A61K0033-14 [I,C*]; A61K0033-14 [I,A]; A61K0033-24 [I,C*];
A61K0033-24 [I,A]; A61K0038-17 [I,C*]; A61K0038-17 [I,A];
A61K0038-18 [I,C*]; A61K0038-18 [I,A]; A61K0038-19 [I,C*];
A61K0038-19 [I,A]; A61K0038-20 [I,C*]; A61K0038-20 [I,A];
A61K0038-24 [I,C*]; A61K0038-24 [I,A]; A61K0038-39 [I,C*];
A61K0038-39 [I,A]; A61K0038-43 [I,C*]; A61K0038-48 [I,A];
A61K0049-00 [I,C*]; A61K0049-00 [I,A]; A61L0027-00 [I,C*];
A61L0027-00 [I,A]; A61L0027-54 [I,A]; A61L0031-00 [I,C*];
A61L0031-00 [I,A]; A61L0031-14 [I,C*]; A61L0031-16 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 8 OF 20 USPATFULL on STN
AN 2005:214575 USPATFULL
TI Medical implants and fibrosis-inducing agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005186247 A1 20050825
AI US 2004-6904 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2003-518785P 20031110 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
DT Utility
FS APPLICATION
LN.CNT 43007
INCL INCLM: 424/423.000
NCL NCLM: 424/423.000
IC [7]
ICM A61F002-00
IPCI A61F0002-00 [ICM,7]
IPCR A61B0017-03 [I,C*]; A61B0017-11 [I,A]; A61B0017-12 [I,C*];
A61B0017-12 [I,A]; A61C0005-00 [I,C*]; A61C0005-00 [I,A];
A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-28 [I,C*];
A61F0002-28 [I,A]; A61F0013-00 [I,C*]; A61F0013-00 [I,A];
A61K0031-045 [I,C*]; A61K0031-045 [I,A]; A61K0031-4738 [I,C*];
A61K0031-4745 [I,A]; A61K0031-513 [I,C*]; A61K0031-513 [I,A];
A61K0031-519 [I,C*]; A61K0031-525 [I,A]; A61K0031-65 [I,C*];
A61K0031-65 [I,A]; A61K0031-70 [I,C*]; A61K0031-70 [I,A];
A61K0031-7012 [I,C*]; A61K0031-7012 [I,A]; A61K0031-7028 [I,C*];
A61K0031-704 [I,A]; A61K0031-7042 [I,C*]; A61K0031-7048 [I,A];
A61K0031-7072 [I,A]; A61K0031-74 [I,C*]; A61K0031-765 [I,A];
A61K0033-14 [I,C*]; A61K0033-14 [I,A]; A61K0033-24 [I,C*];
A61K0033-24 [I,A]; A61K0038-17 [I,C*]; A61K0038-17 [I,A];
A61K0038-18 [I,C*]; A61K0038-18 [I,A]; A61K0038-19 [I,C*];
A61K0038-19 [I,A]; A61K0038-20 [I,C*]; A61K0038-20 [I,A];
A61K0038-24 [I,C*]; A61K0038-24 [I,A]; A61K0038-39 [I,C*];
A61K0038-39 [I,A]; A61K0038-43 [I,C*]; A61K0038-48 [I,A];
A61K0049-00 [I,C*]; A61K0049-00 [I,A]; A61L0027-00 [I,C*];
A61L0027-00 [I,A]; A61L0027-54 [I,A]; A61L0031-00 [I,C*];
A61L0031-00 [I,A]; A61L0031-14 [I,C*]; A61L0031-16 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 9 OF 20 USPATFULL on STN
AN 2005:212065 USPATFULL
TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND, 6304 (non-U.S. corporation)
PI US 2005183728 A1 20050825
AI US 2004-7836 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2003-518785P 20031110 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2003-525226P 20031124 (60)
US 2003-526541P 20031203 (60)

```
       US 2004-586861P     20040709 (60)
       US 2004-578471P     20040609 (60)
DT     Utility
FS     APPLICATION
LN.CNT 56413
INCL   INCLM: 128/207.140
NCL    NCLM:  128/207.140
IC     [7]
       ICM    A61M016-04
       ICS    A62B009-00
       IPCI   A61M0016-04 [ICM,7]; A62B0009-00 [ICS,7]
       IPCR   A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-02 [I,C*];
              A61F0002-02 [I,A]; A61F0002-04 [I,C*]; A61F0002-04 [I,A];
              A61F0002-06 [I,C*]; A61F0002-06 [I,A]; A61F0002-28 [I,C*];
              A61F0002-28 [I,A]; A61F0002-44 [I,C*]; A61F0002-44 [I,A];
              A61K0038-00 [I,C*]; A61K0038-00 [I,A]; A61L0031-14 [I,C*];
              A61L0031-16 [I,A]; A61M0016-04 [I,C*]; A61M0016-04 [I,A];
              A61M0031-00 [I,C*]; A61M0031-00 [I,A]; A61N0001-05 [I,C*];
              A61N0001-05 [I,A]; A62B0009-00 [I,C*]; A62B0009-00 [I,A]

L13  ANSWER 10 OF 20  USPATFULL on STN
AN     2005:209494  USPATFULL
TI     Medical implants and anti-scarring agents
IN     Hunter, William L., Vancouver, CANADA
       Gravett, David M., Vancouver, CANADA
       Toleikis, Philip M., Vancouver, CANADA
       Maiti, Arpita, Vancouver, CANADA
       Signore, Pierre E., Vancouver, CANADA
       Liggins, Richard T., Coquitlam, CANADA
PA     Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI     US 2005181977       A1  20050818
AI     US 2004-986231      A1  20041110 (10)
PRAI   US 2003-518785P     20031110 (60)
       US 2003-523908P     20031120 (60)
       US 2003-524023P     20031120 (60)
       US 2003-525226P     20031124 (60)
       US 2003-526541P     20031203 (60)
       US 2004-586861P     20040709 (60)
       US 2004-578471P     20040609 (60)
DT     Utility
FS     APPLICATION
LN.CNT 56396
INCL   INCLM: 514/002.000
       INCLS: 623/001.490
NCL    NCLM:  514/002.000
       NCLS:  623/001.490
IC     [7]
       ICM    A61K038-00
       ICS    A61F002-06
       IPCI   A61K0038-00 [ICM,7]; A61F0002-06 [ICS,7]
       IPCR   A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-02 [I,C*];
              A61F0002-02 [I,A]; A61F0002-04 [I,C*]; A61F0002-04 [I,A];
              A61F0002-06 [I,C*]; A61F0002-06 [I,A]; A61F0002-28 [I,C*];
              A61F0002-28 [I,A]; A61F0002-44 [I,C*]; A61F0002-44 [I,A];
              A61K0038-00 [I,C*]; A61K0038-00 [I,A]; A61L0031-14 [I,C*];
              A61L0031-16 [I,A]; A61M0016-04 [I,C*]; A61M0016-04 [I,A];
              A61M0031-00 [I,C*]; A61M0031-00 [I,A]; A61N0001-05 [I,C*];
              A61N0001-05 [I,A]; A62B0009-00 [I,C*]; A62B0009-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13  ANSWER 11 OF 20  USPATFULL on STN
AN     2005:208533  USPATFULL
```

TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
    Gravett, David M., Vancouver, CANADA
    Toleikis, Philip M., Vancouver, CANADA
    Maiti, Arpita, Vancouver, CANADA
    Signore, Pierre E., Vancouver, CANADA
    Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005181011 A1 20050818
AI US 2004-1792 A1 20041202 (11)
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2003-518785P 20031110 (60)
    US 2003-523908P 20031120 (60)
    US 2003-524023P 20031120 (60)
    US 2003-525226P 20031124 (60)
    US 2003-526541P 20031203 (60)
    US 2004-586861P 20040709 (60)
    US 2004-578471P 20040609 (60)
DT Utility
FS APPLICATION
LN.CNT 56421
INCL INCLM: 424/423.000
    INCLS: 623/016.110
NCL NCLM: 424/423.000
    NCLS: 623/016.110
IC [7]
    ICM A61F002-28
    ICS A61F002-44
    IPCI A61F0002-28 [ICM,7]; A61F0002-44 [ICS,7]
    IPCR A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-02 [I,C*];
          A61F0002-02 [I,A]; A61F0002-04 [I,C*]; A61F0002-04 [I,A];
          A61F0002-06 [I,C*]; A61F0002-06 [I,A]; A61F0002-28 [I,C*];
          A61F0002-28 [I,A]; A61F0002-44 [I,C*]; A61F0002-44 [I,A];
          A61K0038-00 [I,C*]; A61K0038-00 [I,A]; A61L0031-14 [I,C*];
          A61L0031-16 [I,A]; A61M0016-04 [I,C*]; A61M0016-04 [I,A];
          A61M0031-00 [I,C*]; A61M0031-00 [I,A]; A61N0001-05 [I,C*];
          A61N0001-05 [I,A]; A62B0009-00 [I,C*]; A62B0009-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 12 OF 20 USPATFULL on STN
AN 2005:208530 USPATFULL
TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
    Gravett, David M., Vancouver, CANADA
    Toleikis, Philip M., Vancouver, CANADA
    Maiti, Arpita, Vancouver, CANADA
    Signore, Pierre E., Vancouver, CANADA
    Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005181008 A1 20050818
AI US 2004-1786 A1 20041202 (11)
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2003-518785P 20031110 (60)
    US 2003-523908P 20031120 (60)
    US 2003-524023P 20031120 (60)
    US 2003-525226P 20031124 (60)
    US 2003-526541P 20031203 (60)
    US 2004-586861P 20040709 (60)
    US 2004-578471P 20040609 (60)
DT Utility
FS APPLICATION
LN.CNT 56377

INCL INCLM: 424/423.000
INCLS: 604/500.000
NCL NCLM: 424/423.000
NCLS: 604/500.000
IC [7]
ICM A61F002-00
ICS A61M031-00
IPCI A61F0002-00 [ICM,7]; A61M0031-00 [ICS,7]
IPCR A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-02 [I,C*];
A61F0002-02 [I,A]; A61F0002-04 [I,C*]; A61F0002-04 [I,A];
A61F0002-06 [I,C*]; A61F0002-06 [I,A]; A61F0002-28 [I,C*];
A61F0002-28 [I,A]; A61F0002-44 [I,C*]; A61F0002-44 [I,A];
A61K0038-00 [I,C*]; A61K0038-00 [I,A]; A61L0031-14 [I,C*];
A61L0031-16 [I,A]; A61M0016-04 [I,C*]; A61M0016-04 [I,A];
A61M0031-00 [I,C*]; A61M0031-00 [I,A]; A61N0001-05 [I,C*];
A61N0001-05 [I,A]; A62B0009-00 [I,C*]; A62B0009-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 13 OF 20 USPATFULL on STN
AN 2005:203799 USPATFULL
TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND, CH (non-U.S. corporation)
PI US 2005177225 A1 20050811
AI US 2004-6895 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2003-518785P 20031110 (60)
DT Utility
FS APPLICATION
LN.CNT 56371
INCL INCLM: 623/001.420
INCLS: 424/423.000; 623/011.110
NCL NCLM: 623/001.420
NCLS: 424/423.000; 623/011.110
IC [7]
ICM A61F002-02
IPCI A61F0002-02 [ICM,7]
IPCR A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-02 [I,C*];
A61F0002-02 [I,A]; A61F0002-04 [I,C*]; A61F0002-04 [I,A];
A61F0002-06 [I,C*]; A61F0002-06 [I,A]; A61F0002-28 [I,C*];
A61F0002-28 [I,A]; A61F0002-44 [I,C*]; A61F0002-44 [I,A];
A61K0038-00 [I,C*]; A61K0038-00 [I,A]; A61L0031-14 [I,C*];
A61L0031-16 [I,A]; A61M0016-04 [I,C*]; A61M0016-04 [I,A];
A61M0031-00 [I,C*]; A61M0031-00 [I,A]; A61N0001-05 [I,C*];
A61N0001-05 [I,A]; A62B0009-00 [I,C*]; A62B0009-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 14 OF 20 USPATFULL on STN
AN 2005:202245 USPATFULL
TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005175663 A1 20050811
AI US 2004-1791 A1 20041202 (11)
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2003-518785P 20031110 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2003-525226P 20031124 (60)
US 2003-526541P 20031203 (60)
US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
DT Utility
FS APPLICATION
LN.CNT 56451
INCL INCLM: 424/423.000
NCL NCLM: 424/423.000
IC [7]
ICM A61F002-00
IPCI A61F0002-00 [ICM,7]
IPCR A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-02 [I,C*];
A61F0002-02 [I,A]; A61F0002-04 [I,C*]; A61F0002-04 [I,A];
A61F0002-06 [I,C*]; A61F0002-06 [I,A]; A61F0002-28 [I,C*];
A61F0002-28 [I,A]; A61F0002-44 [I,C*]; A61F0002-44 [I,A];
A61K0038-00 [I,C*]; A61K0038-00 [I,A]; A61L0031-14 [I,C*];
A61L0031-16 [I,A]; A61M0016-04 [I,C*]; A61M0016-04 [I,A];
A61M0031-00 [I,C*]; A61M0031-00 [I,A]; A61N0001-05 [I,C*];
A61N0001-05 [I,A]; A62B0009-00 [I,C*]; A62B0009-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 15 OF 20 USPATFULL on STN
AN 2005:202239 USPATFULL
TI Medical implants and fibrosis-inducing agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CA, UNITED STATES
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005175657 A1 20050811
AI US 2004-4673 A1 20041202 (11)
RLI Continuation of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2003-518785P 20031110 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
DT Utility
FS APPLICATION
LN.CNT 42820
INCL INCLM: 424/422.000
NCL NCLM: 424/422.000
IC [7]
ICM A61F013-00
IPCI A61F0013-00 [ICM,7]
IPCR A61B0017-03 [I,C*]; A61B0017-11 [I,A]; A61B0017-12 [I,C*];
A61B0017-12 [I,A]; A61C0005-00 [I,C*]; A61C0005-00 [I,A];

A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-28 [I,C*];
A61F0002-28 [I,A]; A61F0013-00 [I,C*]; A61F0013-00 [I,A];
A61K0031-045 [I,C*]; A61K0031-045 [I,A]; A61K0031-4738 [I,C*];
A61K0031-4745 [I,A]; A61K0031-513 [I,C*]; A61K0031-513 [I,A];
A61K0031-519 [I,C*]; A61K0031-525 [I,A]; A61K0031-65 [I,C*];
A61K0031-65 [I,A]; A61K0031-70 [I,C*]; A61K0031-70 [I,A];
A61K0031-7012 [I,C*]; A61K0031-7012 [I,A]; A61K0031-7028 [I,C*];
A61K0031-704 [I,A]; A61K0031-7042 [I,C*]; A61K0031-7048 [I,A];
A61K0031-7072 [I,A]; A61K0031-74 [I,C*]; A61K0031-765 [I,A];
A61K0033-14 [I,C*]; A61K0033-14 [I,A]; A61K0033-24 [I,C*];
A61K0033-24 [I,A]; A61K0038-17 [I,C*]; A61K0038-17 [I,A];
A61K0038-18 [I,C*]; A61K0038-18 [I,A]; A61K0038-19 [I,C*];
A61K0038-19 [I,A]; A61K0038-20 [I,C*]; A61K0038-20 [I,A];
A61K0038-24 [I,C*]; A61K0038-24 [I,A]; A61K0038-39 [I,C*];
A61K0038-39 [I,A]; A61K0038-43 [I,C*]; A61K0038-48 [I,A];
A61K0049-00 [I,C*]; A61K0049-00 [I,A]; A61L0027-00 [I,C*];
A61L0027-00 [I,A]; A61L0027-54 [I,A]; A61L0031-00 [I,C*];
A61L0031-00 [I,A]; A61L0031-14 [I,C*]; A61L0031-16 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 16 OF 20 USPATFULL on STN
AN 2005:195817 USPATFULL
TI Medical implants and fibrosis-inducing agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND, 6304 (non-U.S. corporation)
PI US 2005169958 A1 20050804
AI US 2004-1420 A1 20041201 (11)
RLI Continuation of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2003-518785P 20031110 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
DT Utility
FS APPLICATION
LN.CNT 43012
INCL INCLM: 424/423.000
INCLS: 623/016.110
NCL NCLM: 424/423.000
NCLS: 623/016.110
IC [7]
ICM A61F002-28
IPCI A61F0002-28 [ICM,7]
IPCR A61B0017-03 [I,C*]; A61B0017-11 [I,A]; A61B0017-12 [I,C*];
A61B0017-12 [I,A]; A61C0005-00 [I,C*]; A61C0005-00 [I,A];
A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-28 [I,C*];
A61F0002-28 [I,A]; A61F0013-00 [I,C*]; A61F0013-00 [I,A];
A61K0031-045 [I,C*]; A61K0031-045 [I,A]; A61K0031-4738 [I,C*];
A61K0031-4745 [I,A]; A61K0031-513 [I,C*]; A61K0031-513 [I,A];
A61K0031-519 [I,C*]; A61K0031-525 [I,A]; A61K0031-65 [I,C*];
A61K0031-65 [I,A]; A61K0031-70 [I,C*]; A61K0031-70 [I,A];
A61K0031-7012 [I,C*]; A61K0031-7012 [I,A]; A61K0031-7028 [I,C*];
A61K0031-704 [I,A]; A61K0031-7042 [I,C*]; A61K0031-7048 [I,A];
A61K0031-7072 [I,A]; A61K0031-74 [I,C*]; A61K0031-765 [I,A];
A61K0033-14 [I,C*]; A61K0033-14 [I,A]; A61K0033-24 [I,C*];
A61K0033-24 [I,A]; A61K0038-17 [I,C*]; A61K0038-17 [I,A];

A61K0038-18 [I,C*]; A61K0038-18 [I,A]; A61K0038-19 [I,C*];
A61K0038-19 [I,A]; A61K0038-20 [I,C*]; A61K0038-20 [I,A];
A61K0038-24 [I,C*]; A61K0038-24 [I,A]; A61K0038-39 [I,C*];
A61K0038-39 [I,A]; A61K0038-43 [I,C*]; A61K0038-48 [I,A];
A61K0049-00 [I,C*]; A61K0049-00 [I,A]; A61L0027-00 [I,C*];
A61L0027-00 [I,A]; A61L0027-54 [I,A]; A61L0031-00 [I,C*];
A61L0031-00 [I,A]; A61L0031-14 [I,C*]; A61L0031-16 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 17 OF 20 USPATFULL on STN
AN 2005:190568 USPATFULL
TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWEDEN (non-U.S. corporation)
PI US 2005165488 A1 20050728
AI US 2004-6912 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2003-518785P 20031110 (60)
DT Utility
FS APPLICATION
LN.CNT 56407
INCL INCLM: 623/017.160
NCL NCLM: 623/017.160
IC [7]
ICM A61F002-44
IPCI A61F0002-44 [ICM,7]
IPCR A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-02 [I,C*];
A61F0002-02 [I,A]; A61F0002-04 [I,C*]; A61F0002-04 [I,A];
A61F0002-06 [I,C*]; A61F0002-06 [I,A]; A61F0002-28 [I,C*];
A61F0002-28 [I,A]; A61F0002-44 [I,C*]; A61F0002-44 [I,A];
A61K0038-00 [I,C*]; A61K0038-00 [I,A]; A61L0031-14 [I,C*];
A61L0031-16 [I,A]; A61M0016-04 [I,C*]; A61M0016-04 [I,A];
A61M0031-00 [I,C*]; A61M0031-00 [I,A]; A61N0001-05 [I,C*];
A61N0001-05 [I,A]; A62B0009-00 [I,C*]; A62B0009-00 [I,A]

L13 ANSWER 18 OF 20 USPATFULL on STN
AN 2005:182891 USPATFULL
TI Medical implants and fibrosis-inducing agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005158274 A1 20050721
AI US 2004-6902 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2003-518785P 20031110 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)

```
       US 2004-586861P     20040709 (60)
       US 2004-578471P     20040609 (60)
DT     Utility
FS     APPLICATION
LN.CNT 43022
INCL   INCLM: 424/078.380
       INCLS: 514/034.000; 514/055.000; 514/049.000; 514/251.000; 514/269.000
NCL    NCLM:  424/078.380
       NCLS:  514/034.000; 514/049.000; 514/055.000; 514/251.000; 514/269.000
IC     [7]
       ICM    A61K031-765
       ICS    A61K031-7072; A61K031-704; A61K031-513; A61K031-525
       IPCI   A61K0031-765 [ICM,7]; A61K0031-74 [ICM,7,C*]; A61K0031-7072
              [ICS,7]; A61K0031-7042 [ICS,7,C*]; A61K0031-704 [ICS,7];
              A61K0031-7028 [ICS,7,C*]; A61K0031-513 [ICS,7]; A61K0031-525
              [ICS,7]; A61K0031-519 [ICS,7,C*]
       IPCR   A61B0017-03 [I,C*]; A61B0017-11 [I,A]; A61B0017-12 [I,C*];
              A61B0017-12 [I,A]; A61C0005-00 [I,C*]; A61C0005-00 [I,A];
              A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-28 [I,C*];
              A61F0002-28 [I,A]; A61F0013-00 [I,C*]; A61F0013-00 [I,A];
              A61K0031-045 [I,C*]; A61K0031-045 [I,A]; A61K0031-4738 [I,C*];
              A61K0031-4745 [I,A]; A61K0031-513 [I,C*]; A61K0031-513 [I,A];
              A61K0031-519 [I,C*]; A61K0031-525 [I,A]; A61K0031-65 [I,C*];
              A61K0031-65 [I,A]; A61K0031-70 [I,C*]; A61K0031-70 [I,A];
              A61K0031-7012 [I,C*]; A61K0031-7012 [I,A]; A61K0031-7028 [I,C*];
              A61K0031-704 [I,A]; A61K0031-7042 [I,C*]; A61K0031-7048 [I,A];
              A61K0031-7072 [I,A]; A61K0031-74 [I,C*]; A61K0031-765 [I,A];
              A61K0033-14 [I,C*]; A61K0033-14 [I,A]; A61K0033-24 [I,C*];
              A61K0033-24 [I,A]; A61K0038-17 [I,C*]; A61K0038-17 [I,A];
              A61K0038-18 [I,C*]; A61K0038-18 [I,A]; A61K0038-19 [I,C*];
              A61K0038-19 [I,A]; A61K0038-20 [I,C*]; A61K0038-20 [I,A];
              A61K0038-24 [I,C*]; A61K0038-24 [I,A]; A61K0038-39 [I,C*];
              A61K0038-39 [I,A]; A61K0038-43 [I,C*]; A61K0038-48 [I,A];
              A61K0049-00 [I,C*]; A61K0049-00 [I,A]; A61L0027-00 [I,C*];
              A61L0027-00 [I,A]; A61L0027-54 [I,A]; A61L0031-00 [I,C*];
              A61L0031-00 [I,A]; A61L0031-14 [I,C*]; A61L0031-16 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13  ANSWER 19 OF 20  USPATFULL on STN
AN     2005:172409  USPATFULL
TI     Medical implants and anti-scarring agents
IN     Hunter, William L., Vancouver, CANADA
       Gravett, David M., Vancouver, CANADA
       Toleikis, Philip M., Vancouver, CANADA
       Maiti, Arpita, Vancouver, CANADA
       Signore, Pierre E., Vancouver, CANADA
       Liggins, Richard T., Coquitlam, CANADA
PA     Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI     US 2005149158       A1  20050707
AI     US 2004-409         A1  20041129 (11)
RLI    Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI   US 2003-518785P     20031110 (60)
       US 2003-523908P     20031120 (60)
       US 2003-524023P     20031120 (60)
       US 2003-525226P     20031124 (60)
       US 2003-526541P     20031203 (60)
       US 2004-586861P     20040709 (60)
       US 2004-578471P     20040609 (60)
DT     Utility
FS     APPLICATION
LN.CNT 56404
INCL   INCLM: 607/119.000
```

```
NCL    NCLM:  607/119.000
IC     [7]
       ICM    A61N001-05
       IPCI   A61N0001-05 [ICM,7]
       IPCR   A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-02 [I,C*];
              A61F0002-02 [I,A]; A61F0002-04 [I,C*]; A61F0002-04 [I,A];
              A61F0002-06 [I,C*]; A61F0002-06 [I,A]; A61F0002-28 [I,C*];
              A61F0002-28 [I,A]; A61F0002-44 [I,C*]; A61F0002-44 [I,A];
              A61K0038-00 [I,C*]; A61K0038-00 [I,A]; A61L0031-14 [I,C*];
              A61L0031-16 [I,A]; A61M0016-04 [I,C*]; A61M0016-04 [I,A];
              A61M0031-00 [I,C*]; A61M0031-00 [I,A]; A61N0001-05 [I,C*];
              A61N0001-05 [I,A]; A62B0009-00 [I,C*]; A62B0009-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13  ANSWER 20 OF 20  USPATFULL on STN
AN     2005:172331  USPATFULL
TI     Medical implants and anti-scarring agents
IN     Hunter, William L., Vancouver, CANADA
       Gravett, David M., Vancouver, CANADA
       Toleikis, Philip M., Vancouver, CANADA
       Maiti, Arpita, Vancouver, CANADA
       Signore, Pierre E., Vancouver, CANADA
       Liggins, Richard T., Coquitlam, CANADA
PA     Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI     US 2005149080       A1  20050707
AI     US 2004-1418        A1  20041130 (11)
RLI    Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI   US 2004-586861P     20040709 (60)
       US 2004-578471P     20040609 (60)
       US 2003-526541P     20031203 (60)
       US 2003-525226P     20031124 (60)
       US 2003-523908P     20031120 (60)
       US 2003-524023P     20031120 (60)
       US 2003-518785P     20031110 (60)
DT     Utility
FS     APPLICATION
LN.CNT 56418
INCL   INCLM: 606/155.000
NCL    NCLM:  606/155.000
IC     [7]
       ICM    A61F002-04
       IPCI   A61F0002-04 [ICM,7]
       IPCR   A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-02 [I,C*];
              A61F0002-02 [I,A]; A61F0002-04 [I,C*]; A61F0002-04 [I,A];
              A61F0002-06 [I,C*]; A61F0002-06 [I,A]; A61F0002-28 [I,C*];
              A61F0002-28 [I,A]; A61F0002-44 [I,C*]; A61F0002-44 [I,A];
              A61K0038-00 [I,C*]; A61K0038-00 [I,A]; A61L0031-14 [I,C*];
              A61L0031-16 [I,A]; A61M0016-04 [I,C*]; A61M0016-04 [I,A];
              A61M0031-00 [I,C*]; A61M0031-00 [I,A]; A61N0001-05 [I,C*];
              A61N0001-05 [I,A]; A62B0009-00 [I,C*]; A62B0009-00 [I,A]


=> s L9 and impreg?(p)bandag?
L14         36 L9 AND IMPREG?(P) BANDAG?

=> d l14 1-36

L14  ANSWER 1 OF 36  CAPLUS  COPYRIGHT 2008 ACS on STN
AN   2004:964610  CAPLUS
DN   141:401038
TI   Ancrod irradiated, impregnated or coated
     sutures and other first aid or wound management bandaging
```

materials for minimizing and/or preventing excessive scar formation
IN Raffaniello, Samn
PA USA
SO U.S. Pat. Appl. Publ., 4 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 20040224006	A1	20041111	US 2004-829143	20040421
PRAI US 2003-464229P	P	20030421		

L14 ANSWER 2 OF 36 USPATFULL on STN
AN 2007:342045 USPATFULL
TI Anti-scarring drug combinations and use thereof
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Grau, Daniel S., Arlington, MA, UNITED STATES
Borisy, Alexis, Arlington, MA, UNITED STATES
Keith, Curtis T., Boston, MA, UNITED STATES
Auspitz, Benjamin A., Cambridge, MA, UNITED STATES
Nichols, M. James, Boston, MA, UNITED STATES
Jost-Price, Edward Roydon, West Roxbury, MA, UNITED STATES
Serbedzija, George N., Sudbury, MA, UNITED STATES
PI US 2007299043 A1 20071227
AI US 2007-732808 A1 20070404 (11)
RLI Continuation-in-part of Ser. No. US 2006-542185, filed on 3 Oct 2006, PENDING
PRAI US 2005-723053P 20051003 (60)
DT Utility
FS APPLICATION
LN.CNT 37332
INCL INCLM: 514/171.000
NCL NCLM: 514/171.000
IC IPCI A61K0031-57 [I,A]; A61P0017-02 [I,A]; A61P0017-00 [I,C*]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 3 OF 36 USPATFULL on STN
AN 2007:237758 USPATFULL
TI Anti-scarring drug combinations and use thereof
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Grau, Daniel S., Arlington, MA, UNITED STATES
Borisy, Alexis, Arlington, MA, UNITED STATES
Keith, Curtis T., Boston, MA, UNITED STATES
Auspitz, Benjamin A., Cambridge, MA, UNITED STATES
Nichols, M. James, Boston, MA, UNITED STATES
Jost-Price, Edward Roydon, West Roxbury, MA, UNITED STATES
Serbedzija, George N., Sudbury, MA, UNITED STATES
PI US 2007208134 A1 20070906
AI US 2006-542185 A1 20061003 (11)
PRAI US 2005-723053P 20051003 (60)
DT Utility
FS APPLICATION
LN.CNT 37771
INCL INCLM: 525/054.100
NCL NCLM: 525/054.100
IC IPCI A61K0047-48 [I,A]

IPCR A61K0047-48 [I,C]; A61K0047-48 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 4 OF 36 USPATFULL on STN
AN 2007:68045 USPATFULL
TI Treatment for heart disease
IN Dinsmore, Jonathan H., Brookline, MA, UNITED STATES
Jacoby, Douglas B., Wellesley, MA, UNITED STATES
PI US 2007059288 A1 20070315
AI US 2006-394537 A1 20060331 (11)
PRAI US 2005-666932P 20050331 (60)
DT Utility
FS APPLICATION
LN.CNT 4110
INCL INCLM: 424/093.200
INCLS: 424/093.700; 514/002.000
NCL NCLM: 424/093.200
NCLS: 424/093.700; 514/002.000
IC IPCI A61K0048-00 [I,A]; A61K0035-14 [I,A]; A61K0038-17 [I,A]
IPCR A61K0048-00 [I,C]; A61K0048-00 [I,A]; A61K0035-14 [I,C];
A61K0035-14 [I,A]; A61K0038-17 [I,C]; A61K0038-17 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 5 OF 36 USPATFULL on STN
AN 2006:174046 USPATFULL
TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2006147492 A1 20060706
AI US 2006-343809 A1 20060131 (11)
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2003-518785P 20031110 (60)
DT Utility
FS APPLICATION
LN.CNT 56233
INCL INCLM: 424/426.000
NCL NCLM: 424/426.000
IC IPCI A61F0002-00 [I,A]; A61K0031-47 [I,A]
IPCR A61F0002-00 [I,A]; A61F0002-00 [I,C]; A61F0002-02 [I,C*];
A61F0002-02 [I,A]; A61F0002-04 [I,C*]; A61F0002-04 [I,A];
A61F0002-06 [I,C*]; A61F0002-06 [I,A]; A61F0002-28 [I,C*];
A61F0002-28 [I,A]; A61F0002-44 [I,C*]; A61F0002-44 [I,A];
A61K0031-47 [I,C]; A61K0031-47 [I,A]; A61K0038-00 [I,C*];
A61K0038-00 [I,A]; A61L0031-14 [I,C*]; A61L0031-16 [I,A];
A61M0016-04 [I,C*]; A61M0016-04 [I,A]; A61M0031-00 [I,C*];
A61M0031-00 [I,A]; A61N0001-05 [I,C*]; A61N0001-05 [I,A];
A62B0009-00 [I,C*]; A62B0009-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 6 OF 36 USPATFULL on STN
AN 2005:240095 USPATFULL

TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A. E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005208095 A1 20050922
AI US 2004-996354 A1 20041122 (10)
RLI Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LN.CNT 34089
INCL INCLM: 424/423.000
NCL NCLM: 424/423.000
IC [7]
ICM A61F002-00
IPCI A61F0002-00 [ICM,7]
IPCR A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61L0027-00 [I,C*]; A61L0027-54 [I,A]; A61L0031-14 [I,C*]; A61L0031-16 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 7 OF 36 USPATFULL on STN
AN 2005:226572 USPATFULL
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005196421 A1 20050908
AI US 2004-1417 A1 20041201 (11)
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-611077P 20040917 (60)
US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LN.CNT 34222
INCL INCLM: 424/423.000
INCLS: 604/500.000
NCL NCLM: 424/423.000
NCLS: 604/500.000
IC [7]

```
       ICM    A61F002-00
       ICS    A61M031-00
       IPCI   A61F0002-00 [ICM,7]; A61M0031-00 [ICS,7]
       IPCR   A61B0019-00 [I,C*]; A61B0019-00 [I,A]; A61F0002-00 [I,C*];
              A61F0002-00 [I,A]; A61F0002-08 [I,C*]; A61F0002-08 [I,A];
              A61F0002-28 [I,C*]; A61F0002-28 [I,A]; A61F0002-44 [I,C*];
              A61F0002-44 [I,A]; A61K0009-14 [I,C*]; A61K0009-14 [I,A];
              A61K0031-337 [I,C*]; A61K0031-337 [I,A]; A61K0031-365 [I,C*];
              A61K0031-365 [I,A]; A61K0031-4738 [I,C*]; A61K0031-4745 [I,A];
              A61K0031-7028 [I,C*]; A61K0031-704 [I,A]; A61K0031-7042 [I,C*];
              A61K0031-7048 [I,A]; A61K0031-7072 [I,A]; A61K0038-00 [I,C*];
              A61K0038-00 [I,A]; A61M0031-00 [I,C*]; A61M0031-00 [I,A];
              A61N0001-00 [I,C*]; A61N0001-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14  ANSWER 8 OF 36  USPATFULL on STN
AN     2005:220596  USPATFULL
TI     Medical implants and anti-scarring agents
IN     Hunter, William L., Vancouver, CANADA
       Gravett, David M., Vancouver, CANADA
       Toleikis, Philip M., Vancouver, CANADA
       Maiti, Arpita, Vancouver, CANADA
       Signore, Pierre E., Vancouver, CANADA
       Liggins, Richard T., Coquitlam, CANADA
PA     Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI     US 2005191331       A1  20050901
AI     US 2004-1419        A1  20041130 (11)
RLI    Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI   US 2003-518785P     20031110 (60)
       US 2003-523908P     20031120 (60)
       US 2003-524023P     20031120 (60)
       US 2003-525226P     20031124 (60)
       US 2003-526541P     20031203 (60)
       US 2004-586861P     20040709 (60)
       US 2004-578471P     20040609 (60)
DT     Utility
FS     APPLICATION
LN.CNT 56419
INCL   INCLM: 424/423.000
NCL    NCLM:  424/423.000
IC     [7]
       ICM    A61F002-00
       IPCI   A61F0002-00 [ICM,7]
       IPCR   A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-02 [I,C*];
              A61F0002-02 [I,A]; A61F0002-04 [I,C*]; A61F0002-04 [I,A];
              A61F0002-06 [I,C*]; A61F0002-06 [I,A]; A61F0002-28 [I,C*];
              A61F0002-28 [I,A]; A61F0002-44 [I,C*]; A61F0002-44 [I,A];
              A61K0038-00 [I,C*]; A61K0038-00 [I,A]; A61L0031-14 [I,C*];
              A61L0031-16 [I,A]; A61M0016-04 [I,C*]; A61M0016-04 [I,A];
              A61M0031-00 [I,C*]; A61M0031-00 [I,A]; A61N0001-05 [I,C*];
              A61N0001-05 [I,A]; A62B0009-00 [I,C*]; A62B0009-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14  ANSWER 9 OF 36  USPATFULL on STN
AN     2005:220513  USPATFULL
TI     Medical implants and fibrosis-inducing agents
IN     Hunter, William L., Vancouver, CANADA
       Gravett, David M., Vancouver, CANADA
       Toleikis, Philip M., Vancouver, CANADA
       Maiti, Arpita, Vancouver, CANADA
       Signore, Pierre E., Vancouver, CANADA
       Liggins, Richard T., Coquitlam, CANADA
```

PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005191248 A1 20050901
AI US 2004-6907 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2003-518785P 20031110 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
DT Utility
FS APPLICATION
LN.CNT 42940
INCL INCLM: 424/050.000
INCLS: 433/217.100
NCL NCLM: 424/050.000
NCLS: 433/217.100
IC [7]
ICM A61K007-28
ICS A61C005-00
IPCI A61K0007-28 [ICM,7]; A61C0005-00 [ICS,7]
IPCR A61B0017-03 [I,C*]; A61B0017-11 [I,A]; A61B0017-12 [I,C*];
A61B0017-12 [I,A]; A61C0005-00 [I,C*]; A61C0005-00 [I,A];
A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-28 [I,C*];
A61F0002-28 [I,A]; A61F0013-00 [I,C*]; A61F0013-00 [I,A];
A61K0031-045 [I,C*]; A61K0031-045 [I,A]; A61K0031-4738 [I,C*];
A61K0031-4745 [I,A]; A61K0031-513 [I,C*]; A61K0031-513 [I,A];
A61K0031-519 [I,C*]; A61K0031-525 [I,A]; A61K0031-65 [I,C*];
A61K0031-65 [I,A]; A61K0031-70 [I,C*]; A61K0031-70 [I,A];
A61K0031-7012 [I,C*]; A61K0031-7012 [I,A]; A61K0031-7028 [I,C*];
A61K0031-704 [I,A]; A61K0031-7042 [I,C*]; A61K0031-7048 [I,A];
A61K0031-7072 [I,A]; A61K0031-74 [I,C*]; A61K0031-765 [I,A];
A61K0033-14 [I,C*]; A61K0033-14 [I,A]; A61K0033-24 [I,C*];
A61K0033-24 [I,A]; A61K0038-17 [I,C*]; A61K0038-17 [I,A];
A61K0038-18 [I,C*]; A61K0038-18 [I,A]; A61K0038-19 [I,C*];
A61K0038-19 [I,A]; A61K0038-20 [I,C*]; A61K0038-20 [I,A];
A61K0038-24 [I,C*]; A61K0038-24 [I,A]; A61K0038-39 [I,C*];
A61K0038-39 [I,A]; A61K0038-43 [I,C*]; A61K0038-48 [I,A];
A61K0049-00 [I,C*]; A61K0049-00 [I,A]; A61L0027-00 [I,C*];
A61L0027-00 [I,A]; A61L0027-54 [I,A]; A61L0031-00 [I,C*];
A61L0031-00 [I,A]; A61L0031-14 [I,C*]; A61L0031-16 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 10 OF 36 USPATFULL on STN
AN 2005:215464 USPATFULL
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A. E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005187140 A1 20050825
AI US 2004-408 A1 20041129 (11)
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,
PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2004-611077P 20040917 (60)

```
       US 2003-526541P     20031203 (60)
       US 2003-525226P     20031124 (60)
       US 2003-523908P     20031120 (60)
DT     Utility
FS     APPLICATION
LN.CNT 34103
INCL   INCLM: 514/002.000
       INCLS: 623/017.110; 623/017.160; 606/076.000
NCL    NCLM:  514/002.000
       NCLS:  606/076.000; 623/017.110; 623/017.160
IC     [7]
       ICM    A61K038-00
       ICS    A61F002-44
       IPCI   A61K0038-00 [ICM,7]; A61F0002-44 [ICS,7]
       IPCR   A61B0019-00 [I,C*]; A61B0019-00 [I,A]; A61F0002-00 [I,C*];
              A61F0002-00 [I,A]; A61F0002-08 [I,C*]; A61F0002-08 [I,A];
              A61F0002-28 [I,C*]; A61F0002-28 [I,A]; A61F0002-44 [I,C*];
              A61F0002-44 [I,A]; A61K0009-14 [I,C*]; A61K0009-14 [I,A];
              A61K0031-337 [I,C*]; A61K0031-337 [I,A]; A61K0031-365 [I,C*];
              A61K0031-365 [I,A]; A61K0031-4738 [I,C*]; A61K0031-4745 [I,A];
              A61K0031-7028 [I,C*]; A61K0031-704 [I,A]; A61K0031-7042 [I,C*];
              A61K0031-7048 [I,A]; A61K0031-7072 [I,A]; A61K0038-00 [I,C*];
              A61K0038-00 [I,A]; A61M0031-00 [I,C*]; A61M0031-00 [I,A];
              A61N0001-00 [I,C*]; A61N0001-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14  ANSWER 11 OF 36  USPATFULL on STN
AN     2005:214575  USPATFULL
TI     Medical implants and fibrosis-inducing agents
IN     Hunter, William L., Vancouver, CANADA
       Gravett, David M., Vancouver, CANADA
       Toleikis, Philip M., Vancouver, CANADA
       Maiti, Arpita, Vancouver, CANADA
       Signore, Pierre E., Vancouver, CANADA
       Liggins, Richard T., Coquitlam, CANADA
PA     Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI     US 2005186247       A1  20050825
AI     US 2004-6904        A1  20041207 (11)
RLI    Continuation of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI   US 2003-518785P     20031110 (60)
       US 2003-523908P     20031120 (60)
       US 2003-524023P     20031120 (60)
       US 2004-586861P     20040709 (60)
       US 2004-578471P     20040609 (60)
DT     Utility
FS     APPLICATION
LN.CNT 43007
INCL   INCLM: 424/423.000
NCL    NCLM:  424/423.000
IC     [7]
       ICM    A61F002-00
       IPCI   A61F0002-00 [ICM,7]
       IPCR   A61B0017-03 [I,C*]; A61B0017-11 [I,A]; A61B0017-12 [I,C*];
              A61B0017-12 [I,A]; A61C0005-00 [I,C*]; A61C0005-00 [I,A];
              A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-28 [I,C*];
              A61F0002-28 [I,A]; A61F0013-00 [I,C*]; A61F0013-00 [I,A];
              A61K0031-045 [I,C*]; A61K0031-045 [I,A]; A61K0031-4738 [I,C*];
              A61K0031-4745 [I,A]; A61K0031-513 [I,C*]; A61K0031-513 [I,A];
              A61K0031-519 [I,C*]; A61K0031-525 [I,A]; A61K0031-65 [I,C*];
              A61K0031-65 [I,A]; A61K0031-70 [I,C*]; A61K0031-70 [I,A];
              A61K0031-7012 [I,C*]; A61K0031-7012 [I,A]; A61K0031-7028 [I,C*];
              A61K0031-704 [I,A]; A61K0031-7042 [I,C*]; A61K0031-7048 [I,A];
```

A61K0031-7072 [I,A]; A61K0031-74 [I,C*]; A61K0031-765 [I,A];
A61K0033-14 [I,C*]; A61K0033-14 [I,A]; A61K0033-24 [I,C*];
A61K0033-24 [I,A]; A61K0038-17 [I,C*]; A61K0038-17 [I,A];
A61K0038-18 [I,C*]; A61K0038-18 [I,A]; A61K0038-19 [I,C*];
A61K0038-19 [I,A]; A61K0038-20 [I,C*]; A61K0038-20 [I,A];
A61K0038-24 [I,C*]; A61K0038-24 [I,A]; A61K0038-39 [I,C*];
A61K0038-39 [I,A]; A61K0038-43 [I,C*]; A61K0038-48 [I,A];
A61K0049-00 [I,C*]; A61K0049-00 [I,A]; A61L0027-00 [I,C*];
A61L0027-00 [I,A]; A61L0027-54 [I,A]; A61L0031-00 [I,C*];
A61L0031-00 [I,A]; A61L0031-14 [I,C*]; A61L0031-16 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 12 OF 36 USPATFULL on STN
AN 2005:214572 USPATFULL
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A. E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005186244 A1 20050825
AI US 2004-1790 A1 20041202 (11)
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-611077P 20040917 (60)
US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LN.CNT 34060
INCL INCLM: 424/423.000
INCLS: 514/002.000; 514/034.000; 514/027.000; 514/283.000
NCL NCLM: 424/423.000
NCLS: 514/002.000; 514/027.000; 514/034.000; 514/283.000
IC [7]
ICM A61K031-7048
ICS A61K031-704; A61K031-4745
IPCI A61K0031-7048 [ICM,7]; A61K0031-7042 [ICM,7,C*]; A61K0031-704 [ICS,7]; A61K0031-7028 [ICS,7,C*]; A61K0031-4745 [ICS,7]; A61K0031-4738 [ICS,7,C*]
IPCR A61B0019-00 [I,C*]; A61B0019-00 [I,A]; A61F0002-00 [I,C*];
A61F0002-00 [I,A]; A61F0002-08 [I,C*]; A61F0002-08 [I,A];
A61F0002-28 [I,C*]; A61F0002-28 [I,A]; A61F0002-44 [I,C*];
A61F0002-44 [I,A]; A61K0009-14 [I,C*]; A61K0009-14 [I,A];
A61K0031-337 [I,C*]; A61K0031-337 [I,A]; A61K0031-365 [I,C*];
A61K0031-365 [I,A]; A61K0031-4738 [I,C*]; A61K0031-4745 [I,A];
A61K0031-7028 [I,C*]; A61K0031-704 [I,A]; A61K0031-7042 [I,C*];
A61K0031-7048 [I,A]; A61K0031-7072 [I,A]; A61K0038-00 [I,C*];
A61K0038-00 [I,A]; A61M0031-00 [I,C*]; A61M0031-00 [I,A];
A61N0001-00 [I,C*]; A61N0001-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 13 OF 36 USPATFULL on STN
AN 2005:212068 USPATFULL

TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A.E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005183731 A1 20050825
AI US 2004-6908 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-611077P 20040917 (60)
US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LN.CNT 34032
INCL INCLM: 128/898.000
INCLS: 623/013.110
NCL NCLM: 128/898.000
NCLS: 623/013.110
IC [7]
ICM A61B019-00
ICS A61F002-08
IPCI A61B0019-00 [ICM,7]; A61F0002-08 [ICS,7]
IPCR A61B0019-00 [I,C*]; A61B0019-00 [I,A]; A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-08 [I,C*]; A61F0002-08 [I,A]; A61F0002-28 [I,C*]; A61F0002-28 [I,A]; A61F0002-44 [I,C*]; A61F0002-44 [I,A]; A61K0009-14 [I,C*]; A61K0009-14 [I,A]; A61K0031-337 [I,C*]; A61K0031-337 [I,A]; A61K0031-365 [I,C*]; A61K0031-365 [I,A]; A61K0031-4738 [I,C*]; A61K0031-4745 [I,A]; A61K0031-7028 [I,C*]; A61K0031-704 [I,A]; A61K0031-7042 [I,C*]; A61K0031-7048 [I,A]; A61K0031-7072 [I,A]; A61K0038-00 [I,C*]; A61K0038-00 [I,A]; A61M0031-00 [I,C*]; A61M0031-00 [I,A]; A61N0001-00 [I,C*]; A61N0001-00 [I,A]

L14 ANSWER 14 OF 36 USPATFULL on STN
AN 2005:212065 USPATFULL
TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND, 6304 (non-U.S. corporation)
PI US 2005183728 A1 20050825
AI US 2004-7836 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2003-518785P 20031110 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2003-525226P 20031124 (60)
US 2003-526541P 20031203 (60)

US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
DT Utility
FS APPLICATION
LN.CNT 56413
INCL INCLM: 128/207.140
NCL NCLM: 128/207.140
IC [7]
ICM A61M016-04
ICS A62B009-00
IPCI A61M0016-04 [ICM,7]; A62B0009-00 [ICS,7]
IPCR A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-02 [I,C*]; A61F0002-02 [I,A]; A61F0002-04 [I,C*]; A61F0002-04 [I,A]; A61F0002-06 [I,C*]; A61F0002-06 [I,A]; A61F0002-28 [I,C*]; A61F0002-28 [I,A]; A61F0002-44 [I,C*]; A61F0002-44 [I,A]; A61K0038-00 [I,C*]; A61K0038-00 [I,A]; A61L0031-14 [I,C*]; A61L0031-16 [I,A]; A61M0016-04 [I,C*]; A61M0016-04 [I,A]; A61M0031-00 [I,C*]; A61M0031-00 [I,A]; A61N0001-05 [I,C*]; A61N0001-05 [I,A]; A62B0009-00 [I,C*]; A62B0009-00 [I,A]

L14 ANSWER 15 OF 36 USPATFULL on STN
AN 2005:209978 USPATFULL
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A. E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND, 6304 (non-U.S. corporation)
PI US 2005182463 A1 20050818
AI US 2004-1788 A1 20041202 (11)
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-611077P 20040917 (60)
US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LN.CNT 34070
INCL INCLM: 607/115.000
INCLS: 604/008.000; 623/011.110
NCL NCLM: 607/115.000
NCLS: 604/008.000; 623/011.110
IC [7]
ICM A61N001-00
IPCI A61N0001-00 [ICM,7]
IPCR A61B0019-00 [I,C*]; A61B0019-00 [I,A]; A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-08 [I,C*]; A61F0002-08 [I,A]; A61F0002-28 [I,C*]; A61F0002-28 [I,A]; A61F0002-44 [I,C*]; A61F0002-44 [I,A]; A61K0009-14 [I,C*]; A61K0009-14 [I,A]; A61K0031-337 [I,C*]; A61K0031-337 [I,A]; A61K0031-365 [I,C*]; A61K0031-365 [I,A]; A61K0031-4738 [I,C*]; A61K0031-4745 [I,A]; A61K0031-7028 [I,C*]; A61K0031-704 [I,A]; A61K0031-7042 [I,C*]; A61K0031-7048 [I,A]; A61K0031-7072 [I,A]; A61K0038-00 [I,C*];

A61K0038-00 [I,A]; A61M0031-00 [I,C*]; A61M0031-00 [I,A];
A61N0001-00 [I,C*]; A61N0001-00 [I,A]

L14 ANSWER 16 OF 36 USPATFULL on STN
AN 2005:209494 USPATFULL
TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005181977 A1 20050818
AI US 2004-986231 A1 20041110 (10)
PRAI US 2003-518785P 20031110 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2003-525226P 20031124 (60)
US 2003-526541P 20031203 (60)
US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
DT Utility
FS APPLICATION
LN.CNT 56396
INCL INCLM: 514/002.000
INCLS: 623/001.490
NCL NCLM: 514/002.000
NCLS: 623/001.490
IC [7]
ICM A61K038-00
ICS A61F002-06
IPCI A61K0038-00 [ICM,7]; A61F0002-06 [ICS,7]
IPCR A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-02 [I,C*];
A61F0002-02 [I,A]; A61F0002-04 [I,C*]; A61F0002-04 [I,A];
A61F0002-06 [I,C*]; A61F0002-06 [I,A]; A61F0002-28 [I,C*];
A61F0002-28 [I,A]; A61F0002-44 [I,C*]; A61F0002-44 [I,A];
A61K0038-00 [I,C*]; A61K0038-00 [I,A]; A61L0031-14 [I,C*];
A61L0031-16 [I,A]; A61M0016-04 [I,C*]; A61M0016-04 [I,A];
A61M0031-00 [I,C*]; A61M0031-00 [I,A]; A61N0001-05 [I,C*];
A61N0001-05 [I,A]; A62B0009-00 [I,C*]; A62B0009-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 17 OF 36 USPATFULL on STN
AN 2005:208533 USPATFULL
TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005181011 A1 20050818
AI US 2004-1792 A1 20041202 (11)
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2003-518785P 20031110 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2003-525226P 20031124 (60)
US 2003-526541P 20031203 (60)
US 2004-586861P 20040709 (60)

```
       US 2004-578471P     20040609 (60)
DT     Utility
FS     APPLICATION
LN.CNT 56421
INCL   INCLM: 424/423.000
       INCLS: 623/016.110
NCL    NCLM:  424/423.000
       NCLS:  623/016.110
IC     [7]
       ICM    A61F002-28
       ICS    A61F002-44
       IPCI   A61F0002-28 [ICM,7]; A61F0002-44 [ICS,7]
       IPCR   A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-02 [I,C*];
              A61F0002-02 [I,A]; A61F0002-04 [I,C*]; A61F0002-04 [I,A];
              A61F0002-06 [I,C*]; A61F0002-06 [I,A]; A61F0002-28 [I,C*];
              A61F0002-28 [I,A]; A61F0002-44 [I,C*]; A61F0002-44 [I,A];
              A61K0038-00 [I,C*]; A61K0038-00 [I,A]; A61L0031-14 [I,C*];
              A61L0031-16 [I,A]; A61M0016-04 [I,C*]; A61M0016-04 [I,A];
              A61M0031-00 [I,C*]; A61M0031-00 [I,A]; A61N0001-05 [I,C*];
              A61N0001-05 [I,A]; A62B0009-00 [I,C*]; A62B0009-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14  ANSWER 18 OF 36  USPATFULL on STN
AN     2005:208530  USPATFULL
TI     Medical implants and anti-scarring agents
IN     Hunter, William L., Vancouver, CANADA
       Gravett, David M., Vancouver, CANADA
       Toleikis, Philip M., Vancouver, CANADA
       Maiti, Arpita, Vancouver, CANADA
       Signore, Pierre E., Vancouver, CANADA
       Liggins, Richard T., Coquitlam, CANADA
PA     Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI     US 2005181008       A1  20050818
AI     US 2004-1786        A1  20041202 (11)
RLI    Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI   US 2003-518785P     20031110 (60)
       US 2003-523908P     20031120 (60)
       US 2003-524023P     20031120 (60)
       US 2003-525226P     20031124 (60)
       US 2003-526541P     20031203 (60)
       US 2004-586861P     20040709 (60)
       US 2004-578471P     20040609 (60)
DT     Utility
FS     APPLICATION
LN.CNT 56377
INCL   INCLM: 424/423.000
       INCLS: 604/500.000
NCL    NCLM:  424/423.000
       NCLS:  604/500.000
IC     [7]
       ICM    A61F002-00
       ICS    A61M031-00
       IPCI   A61F0002-00 [ICM,7]; A61M0031-00 [ICS,7]
       IPCR   A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-02 [I,C*];
              A61F0002-02 [I,A]; A61F0002-04 [I,C*]; A61F0002-04 [I,A];
              A61F0002-06 [I,C*]; A61F0002-06 [I,A]; A61F0002-28 [I,C*];
              A61F0002-28 [I,A]; A61F0002-44 [I,C*]; A61F0002-44 [I,A];
              A61K0038-00 [I,C*]; A61K0038-00 [I,A]; A61L0031-14 [I,C*];
              A61L0031-16 [I,A]; A61M0016-04 [I,C*]; A61M0016-04 [I,A];
              A61M0031-00 [I,C*]; A61M0031-00 [I,A]; A61N0001-05 [I,C*];
              A61N0001-05 [I,A]; A62B0009-00 [I,C*]; A62B0009-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```

L14 ANSWER 19 OF 36 USPATFULL on STN
AN 2005:205930 USPATFULL
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A. E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005178396 A1 20050818
AI US 2004-6905 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-611077P 20040917 (60)
US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LN.CNT 33965
INCL INCLM: 128/898.000
INCLS: 623/014.120
NCL NCLM: 128/898.000
NCLS: 623/014.120
IC [7]
ICM A61B019-00
ICS A61F002-28
IPCI A61B0019-00 [ICM,7]; A61F0002-28 [ICS,7]
IPCR A61B0019-00 [I,C*]; A61B0019-00 [I,A]; A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-08 [I,C*]; A61F0002-08 [I,A]; A61F0002-28 [I,C*]; A61F0002-28 [I,A]; A61F0002-44 [I,C*]; A61F0002-44 [I,A]; A61K0009-14 [I,C*]; A61K0009-14 [I,A]; A61K0031-337 [I,C*]; A61K0031-337 [I,A]; A61K0031-365 [I,C*]; A61K0031-365 [I,A]; A61K0031-4738 [I,C*]; A61K0031-4745 [I,A]; A61K0031-7028 [I,C*]; A61K0031-704 [I,A]; A61K0031-7042 [I,C*]; A61K0031-7048 [I,A]; A61K0031-7072 [I,A]; A61K0038-00 [I,C*]; A61K0038-00 [I,A]; A61M0031-00 [I,C*]; A61M0031-00 [I,A]; A61N0001-00 [I,C*]; A61N0001-00 [I,A]

L14 ANSWER 20 OF 36 USPATFULL on STN
AN 2005:205929 USPATFULL
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A. E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005178395 A1 20050818
AI US 2004-6900 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,

PENDING
PRAI US 2004-611077P 20040917 (60)
US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LN.CNT 34043
INCL INCLM: 128/898.000
NCL NCLM: 128/898.000
IC [7]
ICM A61B019-00
IPCI A61B0019-00 [ICM,7]
IPCR A61B0019-00 [I,C*]; A61B0019-00 [I,A]; A61F0002-00 [I,C*];
A61F0002-00 [I,A]; A61F0002-08 [I,C*]; A61F0002-08 [I,A];
A61F0002-28 [I,C*]; A61F0002-28 [I,A]; A61F0002-44 [I,C*];
A61F0002-44 [I,A]; A61K0009-14 [I,C*]; A61K0009-14 [I,A];
A61K0031-337 [I,C*]; A61K0031-337 [I,A]; A61K0031-365 [I,C*];
A61K0031-365 [I,A]; A61K0031-4738 [I,C*]; A61K0031-4745 [I,A];
A61K0031-7028 [I,C*]; A61K0031-704 [I,A]; A61K0031-7042 [I,C*];
A61K0031-7048 [I,A]; A61K0031-7072 [I,A]; A61K0038-00 [I,C*];
A61K0038-00 [I,A]; A61M0031-00 [I,C*]; A61M0031-00 [I,A];
A61N0001-00 [I,C*]; A61N0001-00 [I,A]

L14 ANSWER 21 OF 36 USPATFULL on STN
AN 2005:203799 USPATFULL
TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND, CH (non-U.S. corporation)
PI US 2005177225 A1 20050811
AI US 2004-6895 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2003-518785P 20031110 (60)
DT Utility
FS APPLICATION
LN.CNT 56371
INCL INCLM: 623/001.420
INCLS: 424/423.000; 623/011.110
NCL NCLM: 623/001.420
NCLS: 424/423.000; 623/011.110
IC [7]
ICM A61F002-02
IPCI A61F0002-02 [ICM,7]
IPCR A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-02 [I,C*];
A61F0002-02 [I,A]; A61F0002-04 [I,C*]; A61F0002-04 [I,A];
A61F0002-06 [I,C*]; A61F0002-06 [I,A]; A61F0002-28 [I,C*];
A61F0002-28 [I,A]; A61F0002-44 [I,C*]; A61F0002-44 [I,A];
A61K0038-00 [I,C*]; A61K0038-00 [I,A]; A61L0031-14 [I,C*];
A61L0031-16 [I,A]; A61M0016-04 [I,C*]; A61M0016-04 [I,A];

A61M0031-00 [I,C*]; A61M0031-00 [I,A]; A61N0001-05 [I,C*];
A61N0001-05 [I,A]; A62B0009-00 [I,C*]; A62B0009-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 22 OF 36 USPATFULL on STN
AN 2005:202285 USPATFULL
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A.E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005175703 A1 20050811
AI US 2004-6888 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-611077P 20040917 (60)
US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LN.CNT 33992
INCL INCLM: 424/486.000
INCLS: 514/283.000; 514/449.000; 514/453.000
NCL NCLM: 424/486.000
NCLS: 514/283.000; 514/449.000; 514/453.000
IC [7]
ICM A61K031-4745
ICS A61K031-365; A61K031-337; A61K009-14
IPCI A61K0031-4745 [ICM,7]; A61K0031-4738 [ICM,7,C*]; A61K0031-365 [ICS,7]; A61K0031-337 [ICS,7]; A61K0009-14 [ICS,7]
IPCR A61B0019-00 [I,C*]; A61B0019-00 [I,A]; A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-08 [I,C*]; A61F0002-08 [I,A]; A61F0002-28 [I,C*]; A61F0002-28 [I,A]; A61F0002-44 [I,C*]; A61F0002-44 [I,A]; A61K0009-14 [I,C*]; A61K0009-14 [I,A]; A61K0031-337 [I,C*]; A61K0031-337 [I,A]; A61K0031-365 [I,C*]; A61K0031-365 [I,A]; A61K0031-4738 [I,C*]; A61K0031-4745 [I,A]; A61K0031-7028 [I,C*]; A61K0031-704 [I,A]; A61K0031-7042 [I,C*]; A61K0031-7048 [I,A]; A61K0031-7072 [I,A]; A61K0038-00 [I,C*]; A61K0038-00 [I,A]; A61M0031-00 [I,C*]; A61M0031-00 [I,A]; A61N0001-00 [I,C*]; A61N0001-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 23 OF 36 USPATFULL on STN
AN 2005:202247 USPATFULL
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A. E., North Vancouver, CANADA

PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005175665 A1 20050811
AI US 2004-6896 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-611077P 20040917 (60)
US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LN.CNT 33978
INCL INCLM: 424/423.000
INCLS: 514/034.000; 514/027.000; 514/283.000; 514/449.000; 514/049.000; 514/575.000
NCL NCLM: 424/423.000
NCLS: 514/027.000; 514/034.000; 514/049.000; 514/283.000; 514/449.000; 514/575.000
IC [7]
ICM A61K031-7048
ICS A61K031-7072; A61K031-337; A61K031-704
IPCI A61K0031-7048 [ICM,7]; A61K0031-7072 [ICS,7]; A61K0031-7042 [ICS,7,C*]; A61K0031-337 [ICS,7]; A61K0031-704 [ICS,7]; A61K0031-7028 [ICS,7,C*]
IPCR A61B0019-00 [I,C*]; A61B0019-00 [I,A]; A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-08 [I,C*]; A61F0002-08 [I,A]; A61F0002-28 [I,C*]; A61F0002-28 [I,A]; A61F0002-44 [I,C*]; A61F0002-44 [I,A]; A61K0009-14 [I,C*]; A61K0009-14 [I,A]; A61K0031-337 [I,C*]; A61K0031-337 [I,A]; A61K0031-365 [I,C*]; A61K0031-365 [I,A]; A61K0031-4738 [I,C*]; A61K0031-4745 [I,A]; A61K0031-7028 [I,C*]; A61K0031-704 [I,A]; A61K0031-7042 [I,C*]; A61K0031-7048 [I,A]; A61K0031-7072 [I,A]; A61K0038-00 [I,C*]; A61K0038-00 [I,A]; A61M0031-00 [I,C*]; A61M0031-00 [I,A]; A61N0001-00 [I,C*]; A61N0001-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 24 OF 36 USPATFULL on STN
AN 2005:202245 USPATFULL
TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005175663 A1 20050811
AI US 2004-1791 A1 20041202 (11)
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2003-518785P 20031110 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2003-525226P 20031124 (60)
US 2003-526541P 20031203 (60)
US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
DT Utility
FS APPLICATION
LN.CNT 56451

INCL INCLM: 424/423.000
NCL NCLM: 424/423.000
IC [7]
  ICM A61F002-00
  IPCI A61F0002-00 [ICM,7]
  IPCR A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-02 [I,C*];
  A61F0002-02 [I,A]; A61F0002-04 [I,C*]; A61F0002-04 [I,A];
  A61F0002-06 [I,C*]; A61F0002-06 [I,A]; A61F0002-28 [I,C*];
  A61F0002-28 [I,A]; A61F0002-44 [I,C*]; A61F0002-44 [I,A];
  A61K0038-00 [I,C*]; A61K0038-00 [I,A]; A61L0031-14 [I,C*];
  A61L0031-16 [I,A]; A61M0016-04 [I,C*]; A61M0016-04 [I,A];
  A61M0031-00 [I,C*]; A61M0031-00 [I,A]; A61N0001-05 [I,C*];
  A61N0001-05 [I,A]; A62B0009-00 [I,C*]; A62B0009-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 25 OF 36 USPATFULL on STN
AN 2005:202239 USPATFULL
TI Medical implants and fibrosis-inducing agents
IN Hunter, William L., Vancouver, CANADA
  Gravett, David M., Vancouver, CANADA
  Toleikis, Philip M., Vancouver, CA, UNITED STATES
  Maiti, Arpita, Vancouver, CANADA
  Signore, Pierre E., Vancouver, CANADA
  Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005175657 A1 20050811
AI US 2004-4673 A1 20041202 (11)
RLI Continuation of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2003-518785P 20031110 (60)
  US 2003-523908P 20031120 (60)
  US 2003-524023P 20031120 (60)
  US 2004-586861P 20040709 (60)
  US 2004-578471P 20040609 (60)
DT Utility
FS APPLICATION
LN.CNT 42820
INCL INCLM: 424/422.000
NCL NCLM: 424/422.000
IC [7]
  ICM A61F013-00
  IPCI A61F0013-00 [ICM,7]
  IPCR A61B0017-03 [I,C*]; A61B0017-11 [I,A]; A61B0017-12 [I,C*];
  A61B0017-12 [I,A]; A61C0005-00 [I,C*]; A61C0005-00 [I,A];
  A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-28 [I,C*];
  A61F0002-28 [I,A]; A61F0013-00 [I,C*]; A61F0013-00 [I,A];
  A61K0031-045 [I,C*]; A61K0031-045 [I,A]; A61K0031-4738 [I,C*];
  A61K0031-4745 [I,A]; A61K0031-513 [I,C*]; A61K0031-513 [I,A];
  A61K0031-519 [I,C*]; A61K0031-525 [I,A]; A61K0031-65 [I,C*];
  A61K0031-65 [I,A]; A61K0031-70 [I,C*]; A61K0031-70 [I,A];
  A61K0031-7012 [I,C*]; A61K0031-7012 [I,A]; A61K0031-7028 [I,C*];
  A61K0031-704 [I,A]; A61K0031-7042 [I,C*]; A61K0031-7048 [I,A];
  A61K0031-7072 [I,A]; A61K0031-74 [I,C*]; A61K0031-765 [I,A];
  A61K0033-14 [I,C*]; A61K0033-14 [I,A]; A61K0033-24 [I,C*];
  A61K0033-24 [I,A]; A61K0038-17 [I,C*]; A61K0038-17 [I,A];
  A61K0038-18 [I,C*]; A61K0038-18 [I,A]; A61K0038-19 [I,C*];
  A61K0038-19 [I,A]; A61K0038-20 [I,C*]; A61K0038-20 [I,A];
  A61K0038-24 [I,C*]; A61K0038-24 [I,A]; A61K0038-39 [I,C*];
  A61K0038-39 [I,A]; A61K0038-43 [I,C*]; A61K0038-48 [I,A];
  A61K0049-00 [I,C*]; A61K0049-00 [I,A]; A61L0027-00 [I,C*];
  A61L0027-00 [I,A]; A61L0027-54 [I,A]; A61L0031-00 [I,C*];
  A61L0031-00 [I,A]; A61L0031-14 [I,C*]; A61L0031-16 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 26 OF 36 USPATFULL on STN
AN 2005:195818 USPATFULL
TI Medical implants and fibrosis-inducing agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005169959 A1 20050804
US 2006240063 A9 20061026
AI US 2004-1421 A1 20041201 (11)
RLI Continuation of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2003-518785P 20031110 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
DT Utility
FS APPLICATION
LN.CNT 15682
INCL INCLM: 424/423.000
INCLS: 623/016.110
NCL NCLM: 424/423.000
NCLS: 623/016.110
IC [7]
ICM A61F002-28
IPCI A61F0002-28 [ICM,7]
IPCI-2 A61F0002-28 [I,A]
IPCR A61F0002-28 [I,C]; A61F0002-28 [I,A]; A61B0017-03 [I,C*];
A61B0017-11 [I,A]; A61B0017-12 [I,C*]; A61B0017-12 [I,A];
A61C0005-00 [I,C*]; A61C0005-00 [I,A]; A61F0002-00 [I,C*];
A61F0002-00 [I,A]; A61F0013-00 [I,C*]; A61F0013-00 [I,A];
A61K0031-045 [I,C*]; A61K0031-045 [I,A]; A61K0031-4738 [I,C*];
A61K0031-4745 [I,A]; A61K0031-513 [I,C*]; A61K0031-513 [I,A];
A61K0031-519 [I,C*]; A61K0031-525 [I,A]; A61K0031-65 [I,C*];
A61K0031-65 [I,A]; A61K0031-70 [I,C*]; A61K0031-70 [I,A];
A61K0031-7012 [I,C*]; A61K0031-7012 [I,A]; A61K0031-7028 [I,C*];
A61K0031-704 [I,A]; A61K0031-7042 [I,C*]; A61K0031-7048 [I,A];
A61K0031-7072 [I,A]; A61K0031-74 [I,C*]; A61K0031-765 [I,A];
A61K0033-14 [I,C*]; A61K0033-14 [I,A]; A61K0033-24 [I,C*];
A61K0033-24 [I,A]; A61K0038-17 [I,C*]; A61K0038-17 [I,A];
A61K0038-18 [I,C*]; A61K0038-18 [I,A]; A61K0038-19 [I,C*];
A61K0038-19 [I,A]; A61K0038-20 [I,C*]; A61K0038-20 [I,A];
A61K0038-24 [I,C*]; A61K0038-24 [I,A]; A61K0038-39 [I,C*];
A61K0038-39 [I,A]; A61K0038-43 [I,C*]; A61K0038-48 [I,A];
A61K0049-00 [I,C*]; A61K0049-00 [I,A]; A61L0027-00 [I,C*];
A61L0027-00 [I,A]; A61L0027-54 [I,A]; A61L0031-00 [I,C*];
A61L0031-00 [I,A]; A61L0031-14 [I,C*]; A61L0031-16 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 27 OF 36 USPATFULL on STN
AN 2005:195817 USPATFULL
TI Medical implants and fibrosis-inducing agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA

PA Angiotech International AG, Zug, SWITZERLAND, 6304 (non-U.S. corporation)
PI US 2005169958 A1 20050804
AI US 2004-1420 A1 20041201 (11)
RLI Continuation of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2003-518785P 20031110 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
DT Utility
FS APPLICATION
LN.CNT 43012
INCL INCLM: 424/423.000
INCLS: 623/016.110
NCL NCLM: 424/423.000
NCLS: 623/016.110
IC [7]
ICM A61F002-28
IPCI A61F0002-28 [ICM,7]
IPCR A61B0017-03 [I,C*]; A61B0017-11 [I,A]; A61B0017-12 [I,C*]; A61B0017-12 [I,A]; A61C0005-00 [I,C*]; A61C0005-00 [I,A]; A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-28 [I,C*]; A61F0002-28 [I,A]; A61F0013-00 [I,C*]; A61F0013-00 [I,A]; A61K0031-045 [I,C*]; A61K0031-045 [I,A]; A61K0031-4738 [I,C*]; A61K0031-4745 [I,A]; A61K0031-513 [I,C*]; A61K0031-513 [I,A]; A61K0031-519 [I,C*]; A61K0031-525 [I,A]; A61K0031-65 [I,C*]; A61K0031-65 [I,A]; A61K0031-70 [I,C*]; A61K0031-70 [I,A]; A61K0031-7012 [I,C*]; A61K0031-7012 [I,A]; A61K0031-7028 [I,C*]; A61K0031-704 [I,A]; A61K0031-7042 [I,C*]; A61K0031-7048 [I,A]; A61K0031-7072 [I,A]; A61K0031-74 [I,C*]; A61K0031-765 [I,A]; A61K0033-14 [I,C*]; A61K0033-14 [I,A]; A61K0033-24 [I,C*]; A61K0033-24 [I,A]; A61K0038-17 [I,C*]; A61K0038-17 [I,A]; A61K0038-18 [I,C*]; A61K0038-18 [I,A]; A61K0038-19 [I,C*]; A61K0038-19 [I,A]; A61K0038-20 [I,C*]; A61K0038-20 [I,A]; A61K0038-24 [I,C*]; A61K0038-24 [I,A]; A61K0038-39 [I,C*]; A61K0038-39 [I,A]; A61K0038-43 [I,C*]; A61K0038-48 [I,A]; A61K0049-00 [I,C*]; A61K0049-00 [I,A]; A61L0027-00 [I,C*]; A61L0027-00 [I,A]; A61L0027-54 [I,A]; A61L0031-00 [I,C*]; A61L0031-00 [I,A]; A61L0031-14 [I,C*]; A61L0031-16 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 28 OF 36 USPATFULL on STN
AN 2005:190568 USPATFULL
TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWEDEN (non-U.S. corporation)
PI US 2005165488 A1 20050728
AI US 2004-6912 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2003-518785P 20031110 (60)

DT Utility
FS APPLICATION
LN.CNT 56407
INCL INCLM: 623/017.160
NCL NCLM: 623/017.160
IC [7]
ICM A61F002-44
IPCI A61F0002-44 [ICM,7]
IPCR A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-02 [I,C*];
A61F0002-02 [I,A]; A61F0002-04 [I,C*]; A61F0002-04 [I,A];
A61F0002-06 [I,C*]; A61F0002-06 [I,A]; A61F0002-28 [I,C*];
A61F0002-28 [I,A]; A61F0002-44 [I,C*]; A61F0002-44 [I,A];
A61K0038-00 [I,C*]; A61K0038-00 [I,A]; A61L0031-14 [I,C*];
A61L0031-16 [I,A]; A61M0016-04 [I,C*]; A61M0016-04 [I,A];
A61M0031-00 [I,C*]; A61M0031-00 [I,A]; A61N0001-05 [I,C*];
A61N0001-05 [I,A]; A62B0009-00 [I,C*]; A62B0009-00 [I,A]

L14 ANSWER 29 OF 36 USPATFULL on STN
AN 2005:182891 USPATFULL
TI Medical implants and fibrosis-inducing agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005158274 A1 20050721
AI US 2004-6902 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2003-518785P 20031110 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
DT Utility
FS APPLICATION
LN.CNT 43022
INCL INCLM: 424/078.380
INCLS: 514/034.000; 514/055.000; 514/049.000; 514/251.000; 514/269.000
NCL NCLM: 424/078.380
NCLS: 514/034.000; 514/049.000; 514/055.000; 514/251.000; 514/269.000
IC [7]
ICM A61K031-765
ICS A61K031-7072; A61K031-704; A61K031-513; A61K031-525
IPCI A61K0031-765 [ICM,7]; A61K0031-74 [ICM,7,C*]; A61K0031-7072
[ICS,7]; A61K0031-7042 [ICS,7,C*]; A61K0031-704 [ICS,7];
A61K0031-7028 [ICS,7,C*]; A61K0031-513 [ICS,7]; A61K0031-525
[ICS,7]; A61K0031-519 [ICS,7,C*]
IPCR A61B0017-03 [I,C*]; A61B0017-11 [I,A]; A61B0017-12 [I,C*];
A61B0017-12 [I,A]; A61C0005-00 [I,C*]; A61C0005-00 [I,A];
A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-28 [I,C*];
A61F0002-28 [I,A]; A61F0013-00 [I,C*]; A61F0013-00 [I,A];
A61K0031-045 [I,C*]; A61K0031-045 [I,A]; A61K0031-4738 [I,C*];
A61K0031-4745 [I,A]; A61K0031-513 [I,C*]; A61K0031-513 [I,A];
A61K0031-519 [I,C*]; A61K0031-525 [I,A]; A61K0031-65 [I,C*];
A61K0031-65 [I,A]; A61K0031-70 [I,C*]; A61K0031-70 [I,A];
A61K0031-7012 [I,C*]; A61K0031-7012 [I,A]; A61K0031-7028 [I,C*];
A61K0031-704 [I,A]; A61K0031-7042 [I,C*]; A61K0031-7048 [I,A];
A61K0031-7072 [I,A]; A61K0031-74 [I,C*]; A61K0031-765 [I,A];
A61K0033-14 [I,C*]; A61K0033-14 [I,A]; A61K0033-24 [I,C*];
A61K0033-24 [I,A]; A61K0038-17 [I,C*]; A61K0038-17 [I,A];

A61K0038-18 [I,C*]; A61K0038-18 [I,A]; A61K0038-19 [I,C*];
A61K0038-19 [I,A]; A61K0038-20 [I,C*]; A61K0038-20 [I,A];
A61K0038-24 [I,C*]; A61K0038-24 [I,A]; A61K0038-39 [I,C*];
A61K0038-39 [I,A]; A61K0038-43 [I,C*]; A61K0038-48 [I,A];
A61K0049-00 [I,C*]; A61K0049-00 [I,A]; A61L0027-00 [I,C*];
A61L0027-00 [I,A]; A61L0027-54 [I,A]; A61L0031-00 [I,C*];
A61L0031-00 [I,A]; A61L0031-14 [I,C*]; A61L0031-16 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 30 OF 36 USPATFULL on STN
AN 2005:172409 USPATFULL
TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005149158 A1 20050707
AI US 2004-409 A1 20041129 (11)
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2003-518785P 20031110 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2003-525226P 20031124 (60)
US 2003-526541P 20031203 (60)
US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
DT Utility
FS APPLICATION
LN.CNT 56404
INCL INCLM: 607/119.000
NCL NCLM: 607/119.000
IC [7]
ICM A61N001-05
IPCI A61N0001-05 [ICM,7]
IPCR A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-02 [I,C*];
A61F0002-02 [I,A]; A61F0002-04 [I,C*]; A61F0002-04 [I,A];
A61F0002-06 [I,C*]; A61F0002-06 [I,A]; A61F0002-28 [I,C*];
A61F0002-28 [I,A]; A61F0002-44 [I,C*]; A61F0002-44 [I,A];
A61K0038-00 [I,C*]; A61K0038-00 [I,A]; A61L0031-14 [I,C*];
A61L0031-16 [I,A]; A61M0016-04 [I,C*]; A61M0016-04 [I,A];
A61M0031-00 [I,C*]; A61M0031-00 [I,A]; A61N0001-05 [I,C*];
A61N0001-05 [I,A]; A62B0009-00 [I,C*]; A62B0009-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 31 OF 36 USPATFULL on STN
AN 2005:172331 USPATFULL
TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005149080 A1 20050707
AI US 2004-1418 A1 20041130 (11)
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)

```
       US 2003-526541P     20031203 (60)
       US 2003-525226P     20031124 (60)
       US 2003-523908P     20031120 (60)
       US 2003-524023P     20031120 (60)
       US 2003-518785P     20031110 (60)
DT     Utility
FS     APPLICATION
LN.CNT 56418
INCL   INCLM: 606/155.000
NCL    NCLM:  606/155.000
IC     [7]
       ICM    A61F002-04
       IPCI   A61F0002-04 [ICM,7]
       IPCR   A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-02 [I,C*];
              A61F0002-02 [I,A]; A61F0002-04 [I,C*]; A61F0002-04 [I,A];
              A61F0002-06 [I,C*]; A61F0002-06 [I,A]; A61F0002-28 [I,C*];
              A61F0002-28 [I,A]; A61F0002-44 [I,C*]; A61F0002-44 [I,A];
              A61K0038-00 [I,C*]; A61K0038-00 [I,A]; A61L0031-14 [I,C*];
              A61L0031-16 [I,A]; A61M0016-04 [I,C*]; A61M0016-04 [I,A];
              A61M0031-00 [I,C*]; A61M0031-00 [I,A]; A61N0001-05 [I,C*];
              A61N0001-05 [I,A]; A62B0009-00 [I,C*]; A62B0009-00 [I,A]

L14  ANSWER 32 OF 36  USPATFULL on STN
AN     2005:171763  USPATFULL
TI     Medical implants and fibrosis-inducing agents
IN     Hunter, William L., Vancouver, CANADA
       Gravett, David M., Vancouver, CANADA
       Toleikis, Philip M., Vancouver, CANADA
       Maiti, Arpita, Vancouver, CANADA
       Signore, Pierre E., Vancouver, CANADA
       Liggins, Richard T., Coquitlam, CANADA
PA     Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI     US 2005148512       A1  20050707
AI     US 2004-986230      A1  20041110 (10)
PRAI   US 2003-518785P     20031110 (60)
       US 2003-523908P     20031120 (60)
       US 2003-524023P     20031120 (60)
       US 2004-586861P     20040709 (60)
       US 2004-578471P     20040609 (60)
DT     Utility
FS     APPLICATION
LN.CNT 42883
INCL   INCLM: 514/012.000
       INCLS: 514/055.000; 514/008.000; 514/053.000; 514/023.000; 514/154.000;
              514/724.000; 424/680.000; 424/085.100; 424/085.200
NCL    NCLM:  514/012.000
       NCLS:  424/085.100; 424/085.200; 424/680.000; 514/008.000; 514/023.000;
              514/053.000; 514/055.000; 514/154.000; 514/724.000
IC     [7]
       ICM    A61K038-17
       ICS    A61K031-7012; A61K031-70; A61K031-65; A61K031-045; A61K033-14;
              A61K038-19; A61K038-20; A61K038-18; A61K038-24
       IPCI   A61K0038-17 [ICM,7]; A61K0031-7012 [ICS,7]; A61K0031-70 [ICS,7];
              A61K0031-65 [ICS,7]; A61K0031-045 [ICS,7]; A61K0033-14 [ICS,7];
              A61K0038-19 [ICS,7]; A61K0038-20 [ICS,7]; A61K0038-18 [ICS,7];
              A61K0038-24 [ICS,7]
       IPCR   A61B0017-03 [I,C*]; A61B0017-11 [I,A]; A61B0017-12 [I,C*];
              A61B0017-12 [I,A]; A61C0005-00 [I,C*]; A61C0005-00 [I,A];
              A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-28 [I,C*];
              A61F0002-28 [I,A]; A61F0013-00 [I,C*]; A61F0013-00 [I,A];
              A61K0031-045 [I,C*]; A61K0031-045 [I,A]; A61K0031-4738 [I,C*];
              A61K0031-4745 [I,A]; A61K0031-513 [I,C*]; A61K0031-513 [I,A];
```

A61K0031-519 [I,C*]; A61K0031-525 [I,A]; A61K0031-65 [I,C*];
A61K0031-65 [I,A]; A61K0031-70 [I,C*]; A61K0031-70 [I,A];
A61K0031-7012 [I,C*]; A61K0031-7012 [I,A]; A61K0031-7028 [I,C*];
A61K0031-704 [I,A]; A61K0031-7042 [I,C*]; A61K0031-7048 [I,A];
A61K0031-7072 [I,A]; A61K0031-74 [I,C*]; A61K0031-765 [I,A];
A61K0033-14 [I,C*]; A61K0033-14 [I,A]; A61K0033-24 [I,C*];
A61K0033-24 [I,A]; A61K0038-17 [I,C*]; A61K0038-17 [I,A];
A61K0038-18 [I,C*]; A61K0038-18 [I,A]; A61K0038-19 [I,C*];
A61K0038-19 [I,A]; A61K0038-20 [I,C*]; A61K0038-20 [I,A];
A61K0038-24 [I,C*]; A61K0038-24 [I,A]; A61K0038-39 [I,C*];
A61K0038-39 [I,A]; A61K0038-43 [I,C*]; A61K0038-48 [I,A];
A61K0049-00 [I,C*]; A61K0049-00 [I,A]; A61L0027-00 [I,C*];
A61L0027-00 [I,A]; A61L0027-54 [I,A]; A61L0031-00 [I,C*];
A61L0031-00 [I,A]; A61L0031-14 [I,C*]; A61L0031-16 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 33 OF 36 USPATFULL on STN
AN 2005:170896 USPATFULL
TI Medical implants and fibrosis-inducing agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005147643 A1 20050707
US 7166570 B2 20070123
AI US 2004-6893 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2003-518785P 20031110 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
DT Utility
FS APPLICATION
LN.CNT 43024
INCL INCLM: 424/423.000
INCLS: 514/012.000; 514/034.000; 514/283.000; 514/027.000; 514/251.000
NCL NCLM: 514/002.000; 424/423.000
NCLS: 530/353.000; 514/012.000; 514/027.000; 514/034.000; 514/251.000;
514/283.000
IC [7]
ICM A61K038-17
ICS A61K031-7048; A61K031-704; A61K031-4745
IPCI A61K0038-17 [ICM,7]; A61K0031-7048 [ICS,7]; A61K0031-7042
[ICS,7,C*]; A61K0031-704 [ICS,7]; A61K0031-7028 [ICS,7,C*];
A61K0031-4745 [ICS,7]; A61K0031-4738 [ICS,7,C*]
IPCI-2 A61K0038-00 [I,A]; A61K0038-17 [I,A]
IPCR A61K0038-00 [I,C]; A61K0038-00 [I,A]; A61B0017-03 [I,C*];
A61B0017-11 [I,A]; A61B0017-12 [I,C*]; A61B0017-12 [I,A];
A61C0005-00 [I,C*]; A61C0005-00 [I,A]; A61F0002-00 [I,C*];
A61F0002-00 [I,A]; A61F0002-28 [I,C*]; A61F0002-28 [I,A];
A61F0013-00 [I,C*]; A61F0013-00 [I,A]; A61K0031-045 [I,C*];
A61K0031-045 [I,A]; A61K0031-4738 [I,C*]; A61K0031-4745 [I,A];
A61K0031-513 [I,C*]; A61K0031-513 [I,A]; A61K0031-519 [I,C*];
A61K0031-525 [I,A]; A61K0031-65 [I,C*]; A61K0031-65 [I,A];
A61K0031-70 [I,C*]; A61K0031-70 [I,A]; A61K0031-7012 [I,C*];
A61K0031-7012 [I,A]; A61K0031-7028 [I,C*]; A61K0031-704 [I,A];
A61K0031-7042 [I,C*]; A61K0031-7048 [I,A]; A61K0031-7072 [I,A];
A61K0031-74 [I,C*]; A61K0031-765 [I,A]; A61K0033-14 [I,C*];

A61K0033-14 [I,A]; A61K0033-24 [I,C*]; A61K0033-24 [I,A];
A61K0038-17 [I,C]; A61K0038-17 [I,A]; A61K0038-18 [I,C*];
A61K0038-18 [I,A]; A61K0038-19 [I,C*]; A61K0038-19 [I,A];
A61K0038-20 [I,C*]; A61K0038-20 [I,A]; A61K0038-24 [I,C*];
A61K0038-24 [I,A]; A61K0038-39 [I,C*]; A61K0038-39 [I,A];
A61K0038-43 [I,C*]; A61K0038-48 [I,A]; A61K0049-00 [I,C*];
A61K0049-00 [I,A]; A61L0027-00 [I,C*]; A61L0027-00 [I,A];
A61L0027-54 [I,A]; A61L0031-00 [I,C*]; A61L0031-00 [I,A];
A61L0031-14 [I,C*]; A61L0031-16 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 34 OF 36 USPATFULL on STN
AN 2005:170852 USPATFULL
TI Medical implants and fibrosis-inducing agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005147599 A1 20050707
AI US 2004-6889 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2003-518785P 20031110 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
DT Utility
FS APPLICATION
LN.CNT 43016
INCL INCLM: 424/094.630
INCLS: 514/049.000; 514/251.000
NCL NCLM: 424/094.630
NCLS: 514/049.000; 514/251.000
IC [7]
ICM A61K038-48
ICS A61K031-525; A61K031-7072
IPCI A61K0038-48 [ICM,7]; A61K0038-43 [ICM,7,C*]; A61K0031-525
[ICS,7]; A61K0031-519 [ICS,7,C*]; A61K0031-7072 [ICS,7];
A61K0031-7042 [ICS,7,C*]
IPCR A61B0017-03 [I,C*]; A61B0017-11 [I,A]; A61B0017-12 [I,C*];
A61B0017-12 [I,A]; A61C0005-00 [I,C*]; A61C0005-00 [I,A];
A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-28 [I,C*];
A61F0002-28 [I,A]; A61F0013-00 [I,C*]; A61F0013-00 [I,A];
A61K0031-045 [I,C*]; A61K0031-045 [I,A]; A61K0031-4738 [I,C*];
A61K0031-4745 [I,A]; A61K0031-513 [I,C*]; A61K0031-513 [I,A];
A61K0031-519 [I,C*]; A61K0031-525 [I,A]; A61K0031-65 [I,C*];
A61K0031-65 [I,A]; A61K0031-70 [I,C*]; A61K0031-70 [I,A];
A61K0031-7012 [I,C*]; A61K0031-7012 [I,A]; A61K0031-7028 [I,C*];
A61K0031-704 [I,A]; A61K0031-7042 [I,C*]; A61K0031-7048 [I,A];
A61K0031-7072 [I,A]; A61K0031-74 [I,C*]; A61K0031-765 [I,A];
A61K0033-14 [I,C*]; A61K0033-14 [I,A]; A61K0033-24 [I,C*];
A61K0033-24 [I,A]; A61K0038-17 [I,C*]; A61K0038-17 [I,A];
A61K0038-18 [I,C*]; A61K0038-18 [I,A]; A61K0038-19 [I,C*];
A61K0038-19 [I,A]; A61K0038-20 [I,C*]; A61K0038-20 [I,A];
A61K0038-24 [I,C*]; A61K0038-24 [I,A]; A61K0038-39 [I,C*];
A61K0038-39 [I,A]; A61K0038-43 [I,C*]; A61K0038-48 [I,A];
A61K0049-00 [I,C*]; A61K0049-00 [I,A]; A61L0027-00 [I,C*];
A61L0027-00 [I,A]; A61L0027-54 [I,A]; A61L0031-00 [I,C*];
A61L0031-00 [I,A]; A61L0031-14 [I,C*]; A61L0031-16 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 35 OF 36 USPATFULL on STN
AN 2005:170815 USPATFULL
TI Medical implants and fibrosis-inducing agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005147562 A1 20050707
AI US 2004-6886 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2003-518785P 20031110 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
DT Utility
FS APPLICATION
LN.CNT 43010
INCL INCLM: 424/009.500
INCLS: 424/423.000; 514/012.000; 514/027.000; 424/649.000; 514/283.000; 514/251.000; 514/575.000
NCL NCLM: 424/009.500
NCLS: 424/423.000; 424/649.000; 514/012.000; 514/027.000; 514/251.000; 514/283.000; 514/575.000
IC [7]
ICM A61K031-7048
ICS A61K049-00; A61K038-17; A61K031-525; A61K031-4745; A61K033-24
IPCI A61K0031-7048 [ICM,7]; A61K0031-7042 [ICM,7,C*]; A61K0049-00 [ICS,7]; A61K0038-17 [ICS,7]; A61K0031-525 [ICS,7]; A61K0031-519 [ICS,7,C*]; A61K0031-4745 [ICS,7]; A61K0031-4738 [ICS,7,C*]; A61K0033-24 [ICS,7]
IPCR A61B0017-03 [I,C*]; A61B0017-11 [I,A]; A61B0017-12 [I,C*]; A61B0017-12 [I,A]; A61C0005-00 [I,C*]; A61C0005-00 [I,A]; A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-28 [I,C*]; A61F0002-28 [I,A]; A61F0013-00 [I,C*]; A61F0013-00 [I,A]; A61K0031-045 [I,C*]; A61K0031-045 [I,A]; A61K0031-4738 [I,C*]; A61K0031-4745 [I,A]; A61K0031-513 [I,C*]; A61K0031-513 [I,A]; A61K0031-519 [I,C*]; A61K0031-525 [I,A]; A61K0031-65 [I,C*]; A61K0031-65 [I,A]; A61K0031-70 [I,C*]; A61K0031-70 [I,A]; A61K0031-7012 [I,C*]; A61K0031-7012 [I,A]; A61K0031-7028 [I,C*]; A61K0031-704 [I,A]; A61K0031-7042 [I,C*]; A61K0031-7048 [I,A]; A61K0031-7072 [I,A]; A61K0031-74 [I,C*]; A61K0031-765 [I,A]; A61K0033-14 [I,C*]; A61K0033-14 [I,A]; A61K0033-24 [I,C*]; A61K0033-24 [I,A]; A61K0038-17 [I,C*]; A61K0038-17 [I,A]; A61K0038-18 [I,C*]; A61K0038-18 [I,A]; A61K0038-19 [I,C*]; A61K0038-19 [I,A]; A61K0038-20 [I,C*]; A61K0038-20 [I,A]; A61K0038-24 [I,C*]; A61K0038-24 [I,A]; A61K0038-39 [I,C*]; A61K0038-39 [I,A]; A61K0038-43 [I,C*]; A61K0038-48 [I,A]; A61K0049-00 [I,C*]; A61K0049-00 [I,A]; A61L0027-00 [I,C*]; A61L0027-00 [I,A]; A61L0027-54 [I,A]; A61L0031-00 [I,C*]; A61L0031-00 [I,A]; A61L0031-14 [I,C*]; A61L0031-16 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 36 OF 36 USPATFULL on STN
AN 2005:164739 USPATFULL
TI Medical implants and fibrosis-inducing agents
IN Hunter, William L., Vancouver, CANADA

```
       Gravett, David M., Vancouver, CANADA
       Toleikis, Philip M., Vancouver, CANADA
       Maiti, Arpita, Vancouver, CANADA
       Signore, Pierre E., Vancouver, CANADA
       Liggins, Richard T., Coquitlam, CANADA
PA     Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI     US 2005142163       A1  20050630
       US 2006240064       A9  20061026
AI     US 2004-1422        A1  20041201 (11)
RLI    Continuation of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI   US 2003-518785P     20031110 (60)
       US 2003-523908P     20031120 (60)
       US 2003-524023P     20031120 (60)
       US 2004-586861P     20040709 (60)
       US 2004-578471P     20040609 (60)
DT     Utility
FS     APPLICATION
LN.CNT 34720
INCL   INCLM: 424/423.000
NCL    NCLM:  424/423.000
IC     [7]
       ICM    A61F002-00
       IPCI   A61F0002-00 [ICM,7]
       IPCI-2 A61F0002-00 [I,A]
       IPCR   A61F0002-00 [I,C]; A61F0002-00 [I,A]; A61B0017-03 [I,C*];
              A61B0017-11 [I,A]; A61B0017-12 [I,C*]; A61B0017-12 [I,A];
              A61C0005-00 [I,C*]; A61C0005-00 [I,A]; A61F0002-28 [I,C*];
              A61F0002-28 [I,A]; A61F0013-00 [I,C*]; A61F0013-00 [I,A];
              A61K0031-045 [I,C*]; A61K0031-045 [I,A]; A61K0031-4738 [I,C*];
              A61K0031-4745 [I,A]; A61K0031-513 [I,C*]; A61K0031-513 [I,A];
              A61K0031-519 [I,C*]; A61K0031-525 [I,A]; A61K0031-65 [I,C*];
              A61K0031-65 [I,A]; A61K0031-70 [I,C*]; A61K0031-70 [I,A];
              A61K0031-7012 [I,C*]; A61K0031-7012 [I,A]; A61K0031-7028 [I,C*];
              A61K0031-704 [I,A]; A61K0031-7042 [I,C*]; A61K0031-7048 [I,A];
              A61K0031-7072 [I,A]; A61K0031-74 [I,C*]; A61K0031-765 [I,A];
              A61K0033-14 [I,C*]; A61K0033-14 [I,A]; A61K0033-24 [I,C*];
              A61K0033-24 [I,A]; A61K0038-17 [I,C*]; A61K0038-17 [I,A];
              A61K0038-18 [I,C*]; A61K0038-18 [I,A]; A61K0038-19 [I,C*];
              A61K0038-19 [I,A]; A61K0038-20 [I,C*]; A61K0038-20 [I,A];
              A61K0038-24 [I,C*]; A61K0038-24 [I,A]; A61K0038-39 [I,C*];
              A61K0038-39 [I,A]; A61K0038-43 [I,C*]; A61K0038-48 [I,A];
              A61K0049-00 [I,C*]; A61K0049-00 [I,A]; A61L0027-00 [I,C*];
              A61L0027-00 [I,A]; A61L0027-54 [I,A]; A61L0031-00 [I,C*];
              A61L0031-00 [I,A]; A61L0031-14 [I,C*]; A61L0031-16 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.


=> d l11 3
      1 ANSWERS ARE AVAILABLE.  SPECIFIED ANSWER NUMBER EXCEEDS ANSWER SET SIZE
The answer numbers requested are not in the answer set.
ENTER ANSWER NUMBER OR RANGE (1):
ENTER ANSWER NUMBER OR RANGE (1):.

L11  ANSWER 1 OF 1  USPATFULL on STN
AN     2007:114745  USPATFULL
TI     Methods and compositions for blocking platelet and cell adhesion, cell
       migration and inflammation
IN     Glidden, Paul F., San Diego, CA, UNITED STATES
PI     US 2007099819       A1  20070503
AI     US 2006-540203      A1  20060928 (11)
PRAI   US 2005-721754P     20050928 (60)
DT     Utility
```

FS   APPLICATION
LN.CNT 2315
INCL   INCLM: 514/002.000
NCL   NCLM: 514/002.000
IC   IPCI   A61K0038-17 [I,A]
       IPCR   A61K0038-17 [I,C]; A61K0038-17 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d l14 3 ab

L14 ANSWER 3 OF 36 USPATFULL on STN
AB   The present invention provides devices or implants that comprise anti-scarring drug combinations, methods or making such devices or implants, and methods of inhibiting fibrosis between the devices or implants and tissue surrounding the devices or implants. The present invention also provides compositions that comprise anti-fibrotic drug combinations, and their uses in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

=> d l14 3

L14 ANSWER 3 OF 36 USPATFULL on STN
AN   2007:237758 USPATFULL
TI   Anti-scarring drug combinations and use thereof
IN   Hunter, William L., Vancouver, CANADA
       Toleikis, Philip M., Vancouver, CANADA
       Gravett, David M., Vancouver, CANADA
       Grau, Daniel S., Arlington, MA, UNITED STATES
       Borisy, Alexis, Arlington, MA, UNITED STATES
       Keith, Curtis T., Boston, MA, UNITED STATES
       Auspitz, Benjamin A., Cambridge, MA, UNITED STATES
       Nichols, M. James, Boston, MA, UNITED STATES
       Jost-Price, Edward Roydon, West Roxbury, MA, UNITED STATES
       Serbedzija, George N., Sudbury, MA, UNITED STATES
PI   US 2007208134   A1 20070906
AI   US 2006-542185   A1 20061003 (11)
PRAI   US 2005-723053P   20051003 (60)
DT   Utility
FS   APPLICATION
LN.CNT 37771
INCL   INCLM: 525/054.100
NCL   NCLM: 525/054.100
IC   IPCI   A61K0047-48 [I,A]
       IPCR   A61K0047-48 [I,C]; A61K0047-48 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d l11 3
      1 ANSWERS ARE AVAILABLE. SPECIFIED ANSWER NUMBER EXCEEDS ANSWER SET SIZE
The answer numbers requested are not in the answer set.
ENTER ANSWER NUMBER OR RANGE (1):.

L11 ANSWER 1 OF 1 USPATFULL on STN
AN   2007:114745 USPATFULL
TI   Methods and compositions for blocking platelet and cell adhesion, cell migration and inflammation
IN   Glidden, Paul F., San Diego, CA, UNITED STATES

PI   US 2007099819   A1 20070503
AI   US 2006-540203   A1 20060928 (11)
PRAI   US 2005-721754P   20050928 (60)
DT   Utility
FS   APPLICATION
LN.CNT 2315
INCL   INCLM: 514/002.000
NCL   NCLM: 514/002.000
IC   IPCI   A61K0038-17 [I,A]
       IPCR   A61K0038-17 [I,C]; A61K0038-17 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d L14 4

L14 ANSWER 4 OF 36 USPATFULL on STN
AN   2007:68045 USPATFULL
TI   Treatment for heart disease
IN   Dinsmore, Jonathan H., Brookline, MA, UNITED STATES
       Jacoby, Douglas B., Wellesley, MA, UNITED STATES
PI   US 2007059288   A1 20070315
AI   US 2006-394537   A1 20060331 (11)
PRAI   US 2005-666932P   20050331 (60)
DT   Utility
FS   APPLICATION
LN.CNT 4110
INCL   INCLM: 424/093.200
       INCLS: 424/093.700; 514/002.000
NCL   NCLM: 424/093.200
       NCLS: 424/093.700; 514/002.000
IC   IPCI   A61K0048-00 [I,A]; A61K0035-14 [I,A]; A61K0038-17 [I,A]
       IPCR   A61K0048-00 [I,C]; A61K0048-00 [I,A]; A61K0035-14 [I,C];
              A61K0035-14 [I,A]; A61K0038-17 [I,C]; A61K0038-17 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d L14 3

L14 ANSWER 3 OF 36 USPATFULL on STN
AN   2007:237758 USPATFULL
TI   Anti-scarring drug combinations and use thereof
IN   Hunter, William L., Vancouver, CANADA
       Toleikis, Philip M., Vancouver, CANADA
       Gravett, David M., Vancouver, CANADA
       Grau, Daniel S., Arlington, MA, UNITED STATES
       Borisy, Alexis, Arlington, MA, UNITED STATES
       Keith, Curtis T., Boston, MA, UNITED STATES
       Auspitz, Benjamin A., Cambridge, MA, UNITED STATES
       Nichols, M. James, Boston, MA, UNITED STATES
       Jost-Price, Edward Roydon, West Roxbury, MA, UNITED STATES
       Serbedzija, George N., Sudbury, MA, UNITED STATES
PI   US 2007208134   A1 20070906
AI   US 2006-542185   A1 20061003 (11)
PRAI   US 2005-723053P   20051003 (60)
DT   Utility
FS   APPLICATION
LN.CNT 37771
INCL   INCLM: 525/054.100
NCL   NCLM: 525/054.100
IC   IPCI   A61K0047-48 [I,A]
       IPCR   A61K0047-48 [I,C]; A61K0047-48 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```
=> d l13 3

L13  ANSWER 3 OF 20  USPATFULL on STN
AN     2007:257685  USPATFULL
TI     Sealants for Skin and Other Tissues
IN     Bowlin, Gary L., Mechanicsville, VA, UNITED STATES
       Simpson, David G., Mechanicsville, VA, UNITED STATES
       Wnek, Gary E., Cleveland, OH, UNITED STATES
       Carr, Marcus E. JR., Holland, PA, UNITED STATES
       Stevens, Peter J., N. Richland Hills, TX, UNITED STATES
       Cadd, Gary, Grapevine, TX, UNITED STATES
       Cohen, I. Kelman, Richmond, VA, UNITED STATES
PI     US 2007225631       A1  20070927
AI     US 2003-588344      A1  20031006 (10)
       WO 2003-US31637         20031006
                               20070108  PCT 371 date
PRAI   US 2002-416026P     20021004 (60)
       US 2002-425949P     20021113 (60)
DT     Utility
FS     APPLICATION
LN.CNT 4946
INCL   INCLM: 602/052.000
       INCLS: 205/050.000; 530/356.000
NCL    NCLM:  602/052.000
       NCLS:  205/050.000; 530/356.000
IC     IPCI   A61F0013-00 [I,A]; A61K0038-17 [I,A]; C07K0001-00 [I,A]
       IPCR   A61F0013-00 [I,C]; A61F0013-00 [I,A]; A61K0038-17 [I,C];
              A61K0038-17 [I,A]; C07K0001-00 [I,C]; C07K0001-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.


=> d l13 3 kwic

L13  ANSWER 3 OF 20  USPATFULL on STN
SUMM    . . . strength and mechanical integrity (for example, sufficient
       integrity to withstand application of pressure to a sealant when used as
       a bandage). Many sealants involve the use of fibrin, a
       component of natural blood clots. Many sealants use the combination of
       fibrinogen. . .
SUMM    . . . tissue or organs, and as sealants that can close, cover,
       obstruct, fill, or seal any type of leak, wound, ulcer, injury
       , opening, hole, or cavity. The sealants can be in the form of a matrix
       and can serve as matrices for. . .
SUMM    . . . rapidly hemorrhaging wounds. In many embodiments, the use of
       the sealants of the present invention helps reduce the degree of
       scar formation in the location of use. In some embodiments, the
       compositions form a matrix, preferably a matrix similar to an. . .
       embodiments, the sealant matrix has a pore size that is small enough to
       be impermeable to red blood cells, thus preventing leaking. In
       some embodiments, the sealant matrix has a pore size that is small
       enough to reduce or to eliminate. . .
SUMM    . . . within the present invention. They are used as hemostatic
       agents to stop bleeding at the site of a wound or injury or at
       the site at which surgery has occurred or will occur. Tissue sealants
       are also used to create an. . . applied in any form. Some preferred
       forms include as a sheet or strip for direct application, a component of
       a bandage or gauze, and a powder or fluff that may
       be packed or sprinkled onto or into a location of a wound or
       injury. In some embodiments, the sealants are combined with
       water absorbent materials to provide water absorbency. Another use of
```

the electroprocessed. . .

SUMM . . . the present invention to provide sealants that can cover, obstruct, fill or seal one or more types of wound, ulcer, injury , hole, leak, cavity, enclosure, or opening in any tissue, organ, or part of any organism.

DRWD . . . of C are silver grains. The silver is present at irregular intervals in all implants due to use of a silver-impregnated dressing placed over the electrospun materials and the INTEGRA.

DETD . . . or agents that can prevent, reduce, or eliminate the flow of a fluid or can assist in repair of an injury or reinforcement of a tissue. The compositions are also used as adhesives for attaching tissues or structures of an organism. . . tissue or organs, and as sealants that can close, cover, obstruct, fill, or seal any type of leak, wound, ulcer, injury, opening, hole, or cavity. The sealants can be in the form of a matrix and can serve as matrices for. . .

DETD . . . any substance, composition, or object that can be used to cover, obstruct, fill, or seal any type of wound, ulcer, injury , hole, leak, cavity, enclosure, or opening in any tissue, organ or part of any organism as well as any composition,. . .

DETD . . . such as sulfonated polyacrylamides are related materials, and electrical conductors such as carbon black, graphite, carbon nanotubes, metal particles, and metal-coated plastic or ceramic materials.

DETD . . . matrix components in some embodiments of tissue sealants. In some embodiments, substances that promote fibrinolysis (e.g. tissue plasminogen activator (TPA), urokinase, streptokinase) and/or substances that inhibit clotting (e.g. heparin, coumarin) are included to slow coagulation or to cause the clot to dissipate. . . clotting, and thus serve as a thrombin mimetic. Examples of this type of venom include, but are not limited to Ancrod (from the Malayan Pit Viper), Batroxobin (from Bothrops atrox), Crotalase (from the Eastern Diamondback), Venzyne (from the Southern Copperhead), and. . .

DETD . . . other openings and cavities. One use is as a hemostatic agent to stop bleeding at the site of a wound, injury, or other bleed. The sealants are used both internally (e.g. upon blood vessels, gut linings, and organs) and externally (e.g.. . . any part of the body. In these embodiments the sealants serve, for example, as the sole component of a hemostatic bandage, as a component of a bandage that includes other elements such as adhesive backings, backings to provide a water barrier around the outside of the wound. . . also used as a treatment for ballistic injuries. Internal uses include, but are not limited to, arresting bleeding from an injury to an organ or blood vessel (for example, resulting from blunt abdominal trauma), perioperative bleeding and post-operative hemorrhage. Post surgical. . .

DETD . . . attached to the vessel. Matrices can also be used as plugs for leaks of cerebrospinal fluid, for example after spinal injury, spinal surgery, duraplasty, epidural anesthetic procedures, or other procedures that may lead to leakage. Yet another use is as an. . .

DETD . . . for use in tissue repair and support such as sutures, surgical and orthopedic screws, and surgical and orthopedic plates, natural coatings or components for synthetic implants, cosmetic implants and supports, repair or structural support for organs or tissues, substance delivery, bioengineering. . .

DETD The electroprocessed sealants are also used to support, reinforce, strengthen or connect tissue or structures that have experienced injury, surgery, or deterioration. For example, matrices can be used in a bladder neck suspension procedure for patients suffering from postpartum. . .

DETD . . . embodiment is use of substances and electroprocessed materials having an antibiotic and anti-inflammatory activity at the location of a

skin injury or treatment site for a skin infection.

DETD . . . applied in any form. Some preferred forms include as a sheet or strip for direct application, a component of a bandage or gauze, microdroplets that, for example, form from an electrospray process, a powder or fluff that may be packed or sprinkled onto or into a location of a wound or injury. In some embodiments, electroprocessed materials are ground or milled to produce fine powders which may be used directly or mixed. . . Some embodiments include elastic electrospun materials, for example a sheet of the electroprocessed material that can be stretched over an injury and released, allowing residual tension to pull the open edges of a wound together. In some embodiments, applying an electroprocessed. . .

DETD . . . used by one of ordinary skill in the art. Other embodiments involve electroprocessed matrices in a sheet serving as a bandage or otherwise packaged for easy use. Preferred unit dosage formulations are those containing a dose or unit, or an appropriate. . .

DETD . . . that can occur with hemostatic agent or sealants in a liquid, gel, or semisolid state is the tendency for a gauze or bandage backing to absorb those sealants when pressure is applied. When this occurs, the sealant or hemostatic agent may adhere to the gauze or bandage and pull away from a wound or other site of application. In some embodiments, the sealants of the present invention remain sufficiently solid that they are not absorbed or otherwise attached to a bandage or gauze and thus do not pull away from a wound or other site of application when a bandage, gauze, or other backing is removed. The invention is not limited to solids and some embodiment have a consistency similar to. . .

DETD . . . materials, and poly(1,5-dioxepan-2-one) and copolymers, thereof. Thus, embodiments include, for example, a highly flexible sealant or matrix placed on an injury site on the liver, a firmer, stiffer sealant or matrix used with bone injuries, and matrices containing a large amount. . .

DETD . . . or circular shape, a rectangular envelope shape, a sheet, a ribbon, a cylinder, a plug to insert into a penetrating injury , a sleeve for placing around a vessel or duct, a nerve guide, skin or muscle patch, a dural patch, a powder, a fluff or batt, a bandage or gauze pad, a fascial sheath, vertebral disc, articular cartilage, knee meniscus, ligament, tendon, or a vascular graft for subsequent use in vivo.. . . This alignment allows the user to tear off strips of an electroprocessed material, for example to be used as a bandage. The matrix can be shaped to fit a defect or site to be filled, such as a site where a tumor has been removed, or an injury site in the skin (a cut, a biopsy site, a hole or other defect) or the location of a missing. . . tissue to be bioengineered. The target in some embodiments is a prosthetic, implant or other object that is to be coated with the electroprocessed material. Examples of coated objects include but are not limited to orthopedic implants or devices (e.g. bone screws, orthopedic spine cages, artificial hip joint. . .

DETD . . . initiator and oxidant (e.g., FeCl.sub.3). Finally, conducting polymers can be grown in the electroprocessed material after electroprocessing by using a matrix-coated conductor as the anode for electrochemical synthesis of, for example, polypyrrole or polyaniline. Materials to be electroprocessed can be added. . .

DETD Electroprocessed sealants are useful in formation of prostheses or for use in connection with prosthesis (e.g., as a coating or an adhesive). One application of the electroprocessed matrices is in the formation of medium and small diameter vascular prostheses. . .

DETD . . . surface area to volume ratio. This is an important property in

some embodiments involving a hemostatic product such as a bandage in which the rate and extent of the coagulation in contact with the bandage in some embodiments are directly related to the surface area available for reaction with the blood components and thereby form. . .

DETD . . . unreacted glutaraldehyde, and then rinsed several times in sterile PBS supplemented with PenStrep antibiotics (Gibco) and cut to fit the injury sites. Each scaffolding was covered with a silver impregnated dressing and sutured in place. A bolster was fitted over the entire injury site to maintain gentle pressure on the dressings and inhibit wound contraction. At intervals the animals were sacrificed and the. . .

DETD (B) Electrospun collagen. The tongue was fully established at the margin of injury in wounds treated with electrospun collagen. (FIG. 8, Panel B) The formation of the epithelial tongue represents an important landmark. . .

DETD . . . Panel C). Scaffolds of electrospun VITROGEN also were densely populated with elongated dermal fibroblasts (arrowheads). At the margin of the injury, tongue formation was well established. Functional blood vessels were present within the matrix. Granulation tissue covered the entire wound site.. . .

DETD (A) INTEGRA. Implants were infiltrated with dermal fibroblasts and tongue formation was evident at the margin of the injury site (FIG. 9, Panel A). The fibroblasts in the INTEGRA were scattered throughout the implanted matrix and did not exhibit. . .

DETD . . . Panel B, arrow). This epithelial layer lacked rete pegs (a histological feature of mature skin), but was continuous across the injury. The epidermis was multilayered and exhibited a well differentiated phenotype. A dense cell population appeared throughout the scaffold. The arrow. . .

DETD . . . above. FIG. 10 shows micrographs (20+) of the wound after seven days. Images were captured in the middle of the injury site just subjacent to free surface of implants (arrowheads denote free surface). The substance resting on the electrospun matrix of. . .

DETD . . . the heart. When a sheet electrospun from fibrinogen (approximately 1 cm by 1 cm) was placed onto this type of injury , it wet almost immediately and contracted onto the injury site. Excess blood that had pooled in the abdominal cavity was blotted with gauze and gentle pressure was applied by hand (fingertip) to the surface of the patch. When the pressure was relieved from the injury site blood was visible oozing outward from underneath the patch site. A second sheet of the same composition and dimensions. . .

DETD After 30-60 seconds a second puncture wound was prepared distal to the initial injury site. Arterial blood flow was evident from this puncture, demonstrating the patency of the aortic tree following treatment with the. . .

DETD . . . rather than a jet of blood). When a single patch of the electrospun fibrinogen was placed onto this type of injury site (1+1 cm square and 300-400 μm thick) bleeding was stopped with the single sheet.

DETD . . . bleeding, although not as rapidly as the sheets of electrospun fibrinogen. A sheet of electrospun collagen applied to a spleen injury wetted nearly immediately and conformed to the shape of injury of the spleen and suppressed bleeding. Similar results were obtained with injuries to the liver. However, sheets of electrospun collagen. . .

DETD . . . A single sheet of electrospun fibrinogen (2 cm in length+1. 2 cm in width+300-500 μm thick) was applied over the injury and compressed for 10 seconds with gentle pressure. The injury remained sealed after releasing pressure for 20 seconds, and the heart continued to contract vigorously. A small

amount of seepage. . . all bleeding stopped. After an additional minute the sheet was removed. A clot was evident around the aorta in the injury site and no additional bleeding was evident even after removal of the sheet. Puncturing the Aorta distal to the initial injury site resulted in a fresh jet of arterial blood. This jet of blood demonstrates the patency of the vessel and. . . that perfusion pressures at the site of the clot were substantial and sufficient to support vigorous bleeding if the original injury site had not been completely sealed by the treatment.

DETD . . . were made by transection of the spleen with scissors. In both cases, the electroprocessed collagen material was applied after the injury with forceps directly to the wound surface. For some liver injuries, the wound was larger than the electroprocessed material, so. . .

CLM What is claimed is:
14. A method of providing physical reinforcement to tissue, repairing an injury or defect in tissue, promoting healing or causing hemostasis comprising applying the composition of claim 1 to tissue requiring physical. . .

=>
Connection closed by remote host

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspt189dxw

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	NOV 21	CAS patent coverage to include exemplified prophetic substances identified in English-, French-, German-, and Japanese-language basic patents from 2004-present
NEWS 3	NOV 26	MARPAT enhanced with FSORT command
NEWS 4	NOV 26	MEDLINE year-end processing temporarily halts availability of new fully-indexed citations
NEWS 5	NOV 26	CHEMSAFE now available on STN Easy
NEWS 6	NOV 26	Two new SET commands increase convenience of STN searching
NEWS 7	DEC 01	ChemPort single article sales feature unavailable
NEWS 8	DEC 12	GBFULL now offers single source for full-text coverage of complete UK patent families
NEWS 9	DEC 17	Fifty-one pharmaceutical ingredients added to PS
NEWS 10	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS 11	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

```
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 22:51:49 ON 19 JAN 2009

=> index bioscience
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.22       0.22

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
       AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,
       CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB,
       DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 22:52:11 ON 19 JAN 2009

68 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> s scar? and defibrino? and bandage?
          1   FILE CAPLUS
          1   FILE IFIPAT
  59 FILES SEARCHED...
          2   FILE USPATFULL
          1   FILE WPIDS
          1   FILE WPINDEX

   5 FILES HAVE ONE OR MORE ANSWERS,   68 FILES SEARCHED IN STNINDEX

L1   QUE SCAR? AND DEFIBRINO? AND BANDAGE?

=> file caplus ifipat uspatfull
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.68       0.90

FILE 'CAPLUS' ENTERED AT 22:53:02 ON 19 JAN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'IFIPAT' ENTERED AT 22:53:02 ON 19 JAN 2009
COPYRIGHT (C) 2009 IFI CLAIMS(R) Patent Services (IFI)

FILE 'USPATFULL' ENTERED AT 22:53:02 ON 19 JAN 2009
CA INDEXING COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l1
L2           4 L1
```

```
=> rem dup l2
DUP IS NOT VALID HERE
The DELETE command is used to remove various items stored by the
system.

To delete a saved query, saved answer set, saved L-number list, SDI
request, batch request, mailing list, or user-defined cluster, format,
or search field, enter the name.  The name may include ?  for left,
right, or simultaneous left and right truncation.

Examples:

  DELETE BIO?/Q          - delete query names starting with BIO
  DELETE ?DRUG/A         - delete answer set names ending with DRUG
  DELETE ?ELEC?/L        - delete L-number lists containing ELEC
  DELETE ANTICOAG/S      - delete SDI request
  DELETE ENZYME/B        - delete batch request
  DELETE .MYCLUSTER      - delete user-defined cluster
  DELETE .MYFORMAT       - delete user-defined display format
  DELETE .MYFIELD        - delete user-defined search field
  DELETE NAMELIST MYLIST - delete mailing list

To delete an ordered document or an offline print, enter its
number.

Examples:

  DELETE P123001C        - delete print request
  DELETE D134002C        - delete document order request

To delete an individual L-number or range of L-numbers, enter the
L-number or L-number range.  You may also enter DELETE LAST followed
by a number, n, to delete the last n L-numbers.  RENUMBER or
NORENUMBER may also be explicitly specified to override the value of
SET RENUMBER.

Examples:

  DELETE L21             - delete a single L-number
  DELETE L3-L6           - delete a range of L-numbers
  DELETE LAST 4          - delete the last 4 L-numbers
  DELETE L33-            - delete L33 and any higher L-number
  DELETE -L55            - delete L55 and any lower L-number
  DELETE L2-L6 RENUMBER - delete a range of L-numbers and
                          renumber remaining L-numbers
  DELETE RENUMBER        - renumber L-numbers after deletion of
                          intermediate L-numbers

Entire sets of saved items, SDI requests, batch requests, user-defined
items, or E-numbers can be deleted.

Examples:

  DELETE SAVED/Q - delete all saved queries
  DELETE SAVED/A - delete all saved answer sets
  DELETE SAVED/L - delete all saved L-number lists
  DELETE SAVED   - delete all saved queries, answer sets,
                   and L-number lists
  DELETE SAVED/S - delete all SDI requests
  DELETE SAVED/B - delete all batch requests
  DELETE CLUSTER - delete all user-defined clusters
```

```
  DELETE FORMAT  - delete all user-defined display formats
  DELETE FIELD   - delete all user-defined search fields
  DELETE SELECT  - delete all E-numbers
  DELETE HISTORY - delete all L-numbers and restart the
                   session at L1

To delete an entire multifile SDI request, enter DELETE and
the name of the request.  To delete a component from the
multifile SDI, enter DELETE and the name of the component.

=> dup reml2
ENTER REMOVE, IDENTIFY, ONLY, OR (?):.
Enter "REMOVE" to identify and remove duplicate answers.
Enter "IDENTIFY" to identify duplicate answers in the answer set.
Enter "ONLY" to identify and create an answer set containing only
duplicate records.
ENTER REMOVE, IDENTIFY, ONLY, OR (?):.
Enter "REMOVE" to identify and remove duplicate answers.
Enter "IDENTIFY" to identify duplicate answers in the answer set.
Enter "ONLY" to identify and create an answer set containing only
duplicate records.
ENTER REMOVE, IDENTIFY, ONLY, OR (?):r
'R' IS NOT VALID HERE
Enter "REMOVE" to identify and remove duplicate answers.
Enter "IDENTIFY" to identify duplicate answers in the answer set.
Enter "ONLY" to identify and create an answer set containing only
duplicate records.
ENTER REMOVE, IDENTIFY, ONLY, OR (?):id
'ID' IS NOT VALID HERE
Enter "REMOVE" to identify and remove duplicate answers.
Enter "IDENTIFY" to identify duplicate answers in the answer set.
Enter "ONLY" to identify and create an answer set containing only
duplicate records.
ENTER REMOVE, IDENTIFY, ONLY, OR (?):.
Enter "REMOVE" to identify and remove duplicate answers.
Enter "IDENTIFY" to identify duplicate answers in the answer set.
Enter "ONLY" to identify and create an answer set containing only
duplicate records.
ENTER REMOVE, IDENTIFY, ONLY, OR (?):
ENTER REMOVE, IDENTIFY, ONLY, OR (?):
ENTER REMOVE, IDENTIFY, ONLY, OR (?):
ENTER REMOVE, IDENTIFY, ONLY, OR (?):
ENTER REMOVE, IDENTIFY, ONLY, OR (?):
YOU HAVE RECEIVED THIS PROMPT MESSAGE  5 CONSECUTIVE TIMES WITHOUT ENTERING A
REQUESTED RESPONSE
Enter "REMOVE" to identify and remove duplicate answers.
Enter "IDENTIFY" to identify duplicate answers in the answer set.
Enter "ONLY" to identify and create an answer set containing only
duplicate records.
IF YOU REQUIRE FURTHER HELP, PLEASE CONTACT YOUR LOCAL HELP DESK
ENTER REMOVE, IDENTIFY, ONLY, OR (?):

ENTER REMOVE, IDENTIFY, ONLY, OR (?):remove
ENTER L# LIST OR (END):end

=> d hist

     (FILE 'HOME' ENTERED AT 22:51:49 ON 19 JAN 2009)

     INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
     AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,
     CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB,
```

```
     DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 22:52:11 ON 19 JAN 2009
                SEA SCAR? AND DEFIBRINO? AND BANDAGE?
               ---------
               1   FILE CAPLUS
               1   FILE IFIPAT
               2   FILE USPATFULL
               1   FILE WPIDS
               1   FILE WPINDEX
L1              QUE SCAR? AND DEFIBRINO? AND BANDAGE?
               ---------

     FILE 'CAPLUS, IFIPAT, USPATFULL' ENTERED AT 22:53:02 ON 19 JAN 2009
L2             4 S L1

=> rem dup l2
DUP IS NOT VALID HERE
The DELETE command is used to remove various items stored by the
system.

To delete a saved query, saved answer set, saved L-number list, SDI
request, batch request, mailing list, or user-defined cluster, format,
or search field, enter the name.  The name may include ?  for left,
right, or simultaneous left and right truncation.

Examples:

  DELETE BIO?/Q          - delete query names starting with BIO
  DELETE ?DRUG/A         - delete answer set names ending with DRUG
  DELETE ?ELEC?/L        - delete L-number lists containing ELEC
  DELETE ANTICOAG/S      - delete SDI request
  DELETE ENZYME/B        - delete batch request
  DELETE .MYCLUSTER      - delete user-defined cluster
  DELETE .MYFORMAT       - delete user-defined display format
  DELETE .MYFIELD        - delete user-defined search field
  DELETE NAMELIST MYLIST - delete mailing list

To delete an ordered document or an offline print, enter its
number.

Examples:

  DELETE P123001C        - delete print request
  DELETE D134002C        - delete document order request

To delete an individual L-number or range of L-numbers, enter the
L-number or L-number range.  You may also enter DELETE LAST followed
by a number, n, to delete the last n L-numbers.  RENUMBER or
NORENUMBER may also be explicitly specified to override the value of
SET RENUMBER.

Examples:

  DELETE L21             - delete a single L-number
  DELETE L3-L6           - delete a range of L-numbers
  DELETE LAST 4          - delete the last 4 L-numbers
  DELETE L33-            - delete L33 and any higher L-number
  DELETE -L55            - delete L55 and any lower L-number
  DELETE L2-L6 RENUMBER - delete a range of L-numbers and
                          renumber remaining L-numbers
  DELETE RENUMBER        - renumber L-numbers after deletion of
                          intermediate L-numbers
```

Entire sets of saved items, SDI requests, batch requests, user-defined items, or E-numbers can be deleted.

Examples:

```
  DELETE SAVED/Q - delete all saved queries
  DELETE SAVED/A - delete all saved answer sets
  DELETE SAVED/L - delete all saved L-number lists
  DELETE SAVED   - delete all saved queries, answer sets,
                   and L-number lists
  DELETE SAVED/S - delete all SDI requests
  DELETE SAVED/B - delete all batch requests
  DELETE CLUSTER - delete all user-defined clusters
  DELETE FORMAT  - delete all user-defined display formats
  DELETE FIELD   - delete all user-defined search fields
  DELETE SELECT  - delete all E-numbers
  DELETE HISTORY - delete all L-numbers and restart the
                   session at L1
```

To delete an entire multifile SDI request, enter DELETE and the name of the request. To delete a component from the multifile SDI, enter DELETE and the name of the component.

```
=> dup rem l2
PROCESSING COMPLETED FOR L2
L3            2 DUP REM L2 (2 DUPLICATES REMOVED)

=> d l3 1-2

L3   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2009 ACS on STN  DUPLICATE 1
AN   2004:964610  CAPLUS
DN   141:401038
TI   Ancrod irradiated, impregnated or coated sutures and other first aid or
     wound management bandaging materials for minimizing and/or preventing
     excessive scar formation
IN   Raffaniello, Samn
PA   USA
SO   U.S. Pat. Appl. Publ., 4 pp.
     CODEN: USXXCO
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     ---------------     ----   --------    --------------------    --------
PI   US 20040224006       A1    20041111    US 2004-829143          20040421
PRAI US 2003-464229P      P     20030421

L3   ANSWER 2 OF 2  USPATFULL on STN
AN     2003:319606  USPATFULL
TI     Composite material for wound repair
IN     Butler, Charles E., Houston, TX, UNITED STATES
PI     US 20030225355      A1  20031204
AI     US 2003-406153      A1  20030401 (10)
RLI    Continuation-in-part of Ser. No. US 1998-164481, filed on 1 Oct 1998,
       PENDING
PRAI   US 2002-369063P     20020401 (60)
DT     Utility
FS     APPLICATION
LN.CNT 1283
INCL   INCLM: 602/048.000
NCL    NCLM:  602/048.000
IC     [7]
```

```
       ICM    A61F013-00
       ICS    A61F015-00
       IPCI   A61F0013-00 [ICM,7]; A61F0015-00 [ICS,7]
       IPCR   A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-02 [N,C*];
              A61F0002-02 [N,A]; A61F0002-28 [N,C*]; A61F0002-28 [N,A];
              A61F0002-30 [N,C*]; A61F0002-30 [N,A]; A61L0027-00 [I,C*];
              A61L0027-36 [I,A]; A61L0027-38 [I,A]; A61L0027-48 [I,A];
              A61L0031-12 [I,C*]; A61L0031-12 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.


=> d l3 1 ab

L3   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2009 ACS on STN  DUPLICATE 1
AB   A method for minimizing scarring and preventing excessive
     scar formation at an injury site is disclosed.  The method
     involves the topical and/or local application of a therapeutically
     effective amount of a defibrinogenating agent or of a fibrinolytic
     agent that may be delivered in an appropriate vehicle in a controlled- or
     timed-release manner.  The defibrinogenating agent or
     fibrinolytic agent is applied as a coating on, or is irradiated or
     impregnated into or onto a delivery vehicle such as, for example, sutures,
     dissolvable sutures, bandages, gauze pads, or other types of
     first aid bandaging materials.  Such application may take the form of a
     controlled- or timed-release aspect of either the vehicle, the delivery
     material or the therapeutic agent, such that the release of the
     therapeutic agent may be regulated to produce an appropriate therapeutic
     pattern or defibrinogenation or fibrinolysis.  In a preferred
     aspect of the invention, the defibrinogenating agent is ancrod,
     and the mode of application is as ancrod-coated sutures.


=> d l3 2 ab

L3   ANSWER 2 OF 2  USPATFULL on STN
AB     A composite comprising a barrier material and a support material used
       for wound or tissue repair. Benefits include decreased adhesion to
       organs or other structures adjacent to the repair site, limited fluid
       flux, increased vascularization and cellular infiltration, decreased
       inflammation and reduced scar tissue formation.


=> d hist

     (FILE 'HOME' ENTERED AT 22:51:49 ON 19 JAN 2009)

     INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
     AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,
     CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB,
     DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 22:52:11 ON 19 JAN 2009
                SEA SCAR? AND DEFIBRINO? AND BANDAGE?
               ---------
               1   FILE CAPLUS
               1   FILE IFIPAT
               2   FILE USPATFULL
               1   FILE WPIDS
               1   FILE WPINDEX
L1              QUE SCAR? AND DEFIBRINO? AND BANDAGE?
               ---------

     FILE 'CAPLUS, IFIPAT, USPATFULL' ENTERED AT 22:53:02 ON 19 JAN 2009
L2             4 S L1
```

```
L3            2 DUP REM L2 (2 DUPLICATES REMOVED)

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      17.80      18.70

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -0.82      -0.82

STN INTERNATIONAL LOGOFF AT 22:56:34 ON 19 JAN 2009
```